Award Number: W81XWH-09-1-0543

TITLE: Role of Cathepsin C During Breast Cancer Metastasis

PRINCIPAL INVESTIGATOR: Brian Ruffell, Ph.D.

CONTRACTING ORGANIZATION: University of California
San Francisco, CA 94143-0962

REPORT DATE: September 2011

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
### Role of Cathepsin C During Breast Cancer Metastasis

The presence of some innate immune cell types in developing neoplasms provides a significant pro-tumor advantage. Myeloid lineage immune cells, such as tumor-associated macrophages (TAMs) and immature myeloid-derived cells/monocytes, promote tumor development by exerting pro-tumor activities including activating angiogenic programs, suppressing anti-tumor immunity, and enhancing migratory and metastatic properties of malignant cells. We have now established in both murine models and human patients that exposure to neoadjuvant chemotherapy induces the recruitment of myeloid populations, including tumor-associated macrophage. Using the dependency of this population on the CSF1/CSF1R pathway for recruitment to the tumor microenvironment, we have demonstrated that preventing macrophage influx improves the response of transgenic mice to chemotherapy, resulting in lower primary tumor and pulmonary metastatic burden. Despite this success, human breast cancers are infiltrated by a wider variety of myeloid populations, for example mast cells, that may share overlapping functions with macrophages but that are not dependent on the CSF1/CSF1R pathway. Identifying common molecular pathways mediating chemoresistance may therefore improve the chance and/or efficacy of clinical translation. Along these lines, preliminary data suggests that CSF1/CSF1R blockage selectively reduces infiltration of an IL-10 producing subpopulation of macrophages, and that blockade of IL-10 signaling may be similarly efficacious to direct macrophage targeting. These studies therefore hold great potential for improving the rate of pathological complete response in patients and prolonging survival.

### Subject Terms
- breast cancer
- mouse models
- inflammation
- proteases
- cathepsin protease
- immune cells
- leukocytes

### Security Classification of:
- a. REPORT: U
- b. ABSTRACT: U
- c. THIS PAGE: U

<table>
<thead>
<tr>
<th>a. REPORT</th>
<th>b. ABSTRACT</th>
<th>c. THIS PAGE</th>
<th>17. LIMITATION OF ABSTRACT</th>
<th>18. NUMBER OF PAGES</th>
<th>19a. NAME OF RESPONSIBLE PERSON</th>
<th>19b. TELEPHONE NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>U</td>
<td>U</td>
<td>UU</td>
<td>65</td>
<td>USAMRMC</td>
<td>(include area code)</td>
</tr>
<tr>
<td>Section</td>
<td>Page</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BODY</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEY RESEARCH ACCOMPLISHMENTS</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REPORTABLE OUTCOMES</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONCLUSION</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIBLIOGRAPHY</td>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APPENDICES</td>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
I. INTRODUCTION:

In an original cohort of mice I described an reduction in the number of metastatic lesions in mice deficient for the cysteine protease cathepsin C. Extensive characterization of these mice revealed expression of cathepsin C in multiple cell types, but did not identify differences between cathepsin C proficient and deficient tumors in terms of leukocytic infiltrate, stromal composition, vasculature, proliferation, cell death, or hypoxia. Analysis of circulating carcinoma cells also found to be unchanged, all of which was detailed in the first annual report.

These findings lead me to both examine lung seeding as a potential mechanism and to enroll an additional cohort of animals into an end stage study of metastatic burden to confirm our original observation. I can now report that lung seeding was unaltered in cathepsin C deficient animals, and that no difference in spontaneous lung metastasis was observed in the second cohort of animals. Based upon these negative results, I have completed the study of cathepsin C in breast cancer metastasis and have submitted a manuscript for publication detailing these findings.

Utilizing the technical expertise gained for this extensive work, I initiated parallel studies to comprehensively profile the leukocytic infiltrate in human breast cancer. This analysis revealed higher proportions of lymphocytes within carcinomas compared to normal tissue, and surprisingly that these proportions were reversed in carcinomas exposed to neoadjuvant chemotherapy. This study is now listed as a new Aim 4 in the statement of work, and has been published in a special breast cancer issue of PNAS.

Based upon these findings in breast cancer, and our recent publication describing that removing macrophages from the microenvironment of mammary carcinomas through targeting of the CSF1-CSF1R pathway improves response to chemotherapy (1), I have detailed a new Aim 5 wherein I will determine the mechanism by which macrophages restrict this response. This may prove critical to understanding the results of future clinical trials involving macrophage-targeted agents, including an upcoming trial based upon our paper in Cancer Discovery. In addition, in an attempt to monitor the effectiveness of agents that reduce macrophage infiltration within tumors, I have collaborated with the laboratory of Dr. Heike Daldrup-Link at Stanford University to investigate whether iron oxide nanoparticles can be used to non-invasively measure macrophage density through MR imaging.
II. RESEARCH ACCOMPLISHMENTS BODY:

AIM 1: DETERMINE THE FUNCTIONAL ROLE OF CATHEPSIN C IN REGULATING LEUKOCYTE INFILTRATION AND BIOACTIVITY IN MAMMARY ADENOCARCINOMA DEVELOPMENT AND METASTASIS

Establish the profile of cells expressing CTSC during tumor development and metastasis:

Profile CTSC expression in mammary and lung tissue of MMTV-PyMT mice by flow cytometry. (months 1-6)

Evaluate cathepsin C activity using a selective probe, FY01, in lysates of purified leukocytes isolated from mammary glands, peripheral blood and lung from MMTV-PyMT mice. (months 3-6)

Quantitatively assess activity of cathepsin C enzymatic substrates in purified leukocytes from PyMT/CC+/− versus PyMT/CC−/− mice using selective protease activity assays (months 6-12)

STATUS: COMPLETE

Assess functional significance of cathepsin C in regulating macrophage phenotype:

Analyze polarization state of tumor-associated macrophages by intracellular staining for cytokine expression. (months 1-6)

Verify macrophage polarization by iNOS and arginase expression levels by real time PCR. (months 6-9)

Compare the ability of PyMT/CC+/− and PyMT/CC−/− tumor-associated macrophages to influence invasive properties of malignant MECs grown as organoids using the 3D organotypic model. (months 6-12)

STATUS: COMPLETE

Evaluate leukocyte infiltration regulated by cathepsin C in PyMT mice:

Analysis of leukocyte infiltration in mammary and lung tumors in PyMT/CC+/− and PyMT/CC−/− mice using multicolor flow cytometry. (months 1-6)

Measure cytokine expression levels in mammary and lung tumors in PyMT/CC+/− and PyMT/CC−/− mice via ELISA. (months 3-9)

Identify leukocyte populations with altered cytokine expression profiles in mammary and lung tumors in PyMT/CC+/− versus PyMT/CC−/− mice using intracellular cytokine staining and multicolor flow cytometry. (months 9-12)

STATUS: COMPLETE
AIM 2: DETERMINE AT WHICH STAGE OF CANCER DEVELOPMENT CATHEPSIN C FUNCTIONALLY REGULATES PULMONARY METASTASIS OF MAMMARY CARCINOGENESIS

Determine if cathepsin C regulates intravasation from primary mammary tumors into the circulation:

Measure the number of circulating neoplastic cells in the blood of PyMT/CC+/+ and PyMT/CC-/- mice at day 85 and 95 using either flow cytometry or PCR. (months 12-18)

Examine directional growth of neoplastic cells in the 3D organotypic model during co-culture with the leukocyte populations identified in Aim 1. (months 12-18)

Examine the ability of leukocyte populations to induce chemotaxis of neoplastic cells using a modified Boyden chamber (months 18-21)

Adoptive transfer of CC+/- and CC-/- splenic T cells into PyMT/CC-/- mice and evaluation of lung metastasis and the number of circulating MECs. (months 18-24)

STATUS: COMPLETE

Determine if cathepsin C regulates MEC survival in blood, lung seeding, or outgrowth:

Generate 4 neoplastic cell lines from PyMT/CC+/+ and PyMT/CC-/- mice that are also transgenic for GFP (2 from early non-invasive mammary tumors and 2 from late, invasive tumors). (months 1-6)

Intravenously inject neoplastic cell lines in wildtype and CC-/- mice and measure MEC survival in the blood, lung infiltration, and outgrowth/tumor progression. (months 12-18)

If extravasation into the lung is affected by cathepsin C expression, then examine rolling, adhesion, and transmigration of neoplastic cell lines on immortalized mouse endothelial cells. (months 18-24)

If tumor growth or development is altered, inject neoplastic cells subcutaneously in a xenograft model along with purified tumor-associated leukocytes and measure early growth. (months 18-24)

STATUS: COMPLETE

Determine if metastasis of mammary tumors is regulated by leukocyte-derived cathepsin C:

Generate bone marrow chimeric mice by using irradiated PyMT/CC+/+ and PyMT/CC-/- mice and the bone marrow from GFP+ and GFP+/CC-/- mice. (months 12-24)
Analyze tumor incidence, growth, progression and metastasis in the four combinations of chimeric mice. (months 18-36)

If tissue cathepsin C expression appears to be important, generate chimeric mice that do not express PyMT and measure tumor growth in a xenograft model and lung metastasis following intravenous injection. (months 18-36)

STATUS: COMPLETE

AIM 3: DEVELOP DIAGNOSTIC AND THERAPEUTIC APPROACHES BASED ON CATHEPSIN C BIOACTIVITY TO IMPROVE BREAST CANCER PATIENT SURVIVAL

Develop a probe to measure cathepsin C activity in live mice:

Generate FY01-GdDTPA and FY01-FITC. (months 12-18)

Adjust animal protocol to include use of FY01-GdDTPA and JCP410. (months 12-18)

Evaluate entrance of labeled FY01 into purified TAMs (months 18-21)

Evaluate entrance of labeled FY01 into TAMs in vivo (months 18-21)

Analyze entrance of FY01-GdDTPA into tumors using MRI. (months 21-24)

STATUS: NOT INITIATED*

Evaluate efficacy of a selective cathepsin C inhibitor in reducing pulmonary metastasis:

Examine the effect of the selective cathepsin C inhibitor JCP410 in the 3D organotypic co-culture model. (months 24-30)

Evaluate the ability of JCP410 to inhibit cathepsin C activity in mammary and lung tumors by analyzing post-injection activity by MRI or staining unfixed tissue sections. (months 24-36)

Evaluate the efficacy of JCP410 in inhibiting pulmonary metastasis through bi-weekly i.p injection in mice of age 60 and 80 days. (months 24-36)

STATUS: NOT INITIATED*

Evaluate cathepsin C activity during human breast cancer progression:

Submit proposal for use of human tissue (months 12-24)
Analyze expression of cathepsin C in fixed sections of human mammary tumors by double staining for cathepsin C and leukocyte markers followed by confocal microscopy. *(months 24-36)*

If cathepsin C expression is observed, measure activity in unfixed tissue sections using FY01-FITC. *(months 24-36)*

Correlate cathepsin C expression and activity with information available about the clinical stage of the cancer and/or the outcome. *(months 30-36)*

Analyze breast cancer tissue microarray data with 10 year follow up data for a correlation between cathepsin C expression and clinical stage and/or outcome. *(months 30-36)*

Evaluate role of human leukocytes to promote invasive growth in the 3D organotypic co-culture model using human breast cancer cell lines *(months 24-30)*

Evaluate ability of JCP410 to inhibit the promotion of invasive growth by leukocytes *(months 30-36)*

**STATUS: WILL NOT BE INITIATED**

*Based on results from Aims 1 and 2, we have revised our hypothesis as it is now clear that cathepsin C is not a significant regulator of mammary carcinogenesis; thus, evaluating cathepsin C in human samples is without merit. Based on this, we have added a new Aim 4 and Aim 5.

#NEW AIM 4: EXAMINE THE COMPOSITION OF LEUKOCYTES WITHIN HUMAN BREAST CARCINOMAS AND NORMAL TISSUE IN THE PRESENCE OR ABSENCE OF NEOADJUVANT THERAPY

**Determine leukocyte composition within normal and tumor tissue:**

Utilize polychromatic flow cytometry to generate leukocyte profiles. *(months 12-24)*

To evaluate the composition of tumor-infiltrating leukocytes in human BC, tumors from 20 patients were evaluated by polychromatic flow cytometry and IHC detection of leukocyte lineages in tissue sections as described in Materials and Methods. Nine invasive ductal carcinomas (IDC) and five invasive lobular carcinomas (ILC) – mostly histological grade two or three – were obtained from patients with no prior exposure to CTX (CTX-naïve) at the time of primary surgery for early stage BC, although one patient had received neoadjuvant tamoxifen. Six tumor samples were obtained from patients previously treated with neoadjuvant CTX prior to resection (CTX-treated), consisting entirely of grade two or three IDC. Notably, three of six CTX-treated tumors were HER2/neu-positive, compared to only one of fourteen CTX-naïve tumors, whereas both groups contained roughly equivalent percentages of tumors negative for estrogen, progesterone and HER2 receptors (triple negative). Ipsilateral nonadjacent tissue was also obtained from seven CTX-naïve and four CTX-treated patients for use as “normal” tissue, in
addition to tissues from two contralateral prophylactic mastectomies from patients with ipsilateral ductal carcinoma in situ (DCIS).

Immune infiltrates detected with the pan-leukocyte marker CD45 were present in both normal and tumor tissue, but with substantially increased density in BC (Fig. 1A). Leukocyte subsets were evaluated using a combination of lineage markers to identify specific subpopulations, with the complexity of these populations shown in Fig. 1B as a percentage of the total number of CD45+ cells in each sample. BC tissues from CTX-naive patients contained infiltrates dominated by T lymphocytes (CD3ε+), with minor populations of natural killer cells (CD3ε−CD56−NKG2D+) and B lymphocytes (CD19/20+HLA-DR+CD3ε). In comparison, myeloid-lineage cells including macrophages (CD14hiCD11b+HLA-DR+) and neutrophils (CD15+CD11b+CD49d+) were more evident in the normal tissue from these patients. A similar immune profile was observed in breast tissues obtained from the two prophylactic mastectomies (Fig 1B).

Evaluate presence of tumor-associated macrophages with CD68, CD163 and/or colony-stimulating factor 1 receptor (CSF1R). (months 18-24)

Macrophages are well established as regulators of murine mammary tumorigenesis (2), where they can represent up to 80% of leukocytes present within late stage mammary carcinomas (3). In human BC, immunoreactivity for CD68 has been used extensively for identification of macrophages, with CD68+ cell density associated with reduced overall survival (1, 4-6).

The high number of CD68+ cells reported in the literature, and shown in Fig. 3A, was in contrast to the limited number of CD14hiCD11b+HLA-DR+ macrophages observed by flow cytometry in the BC suspensions examined. To understand this discrepancy, we first evaluated CD68 expression in BC tissue sections, as compared to CD163 (a hemoglobin scavenger

---

Fig. 1. Leukocyte infiltration of human breast tumors. (A) Hematoxylin and eosin (H&E) staining of tissue sections (left panels) with representative immunohistochemistry for CD45 shown for each (right panels). (B) Flow cytometric analysis of leukocyte populations within human breast tumors. Results are shown as a percent of total CD45+ cells with markers used to define specific lineages shown below.
Fig. 2. CD68 is not a specific macrophage marker in human breast tumor tissue. (A) Representative immunohistochemistry within tumors for CD68 (left), CSF1R (middle), and CD163 (right) in serial sections from a CTX-treated patient. Red arrows indicate cells displayed in enlarged insets. (B) Immunofluorescent staining of human breast tumors for CD68 (red) in conjunction with CSF1R (i-ii) or CD45 (iii-iv). (C) Immunofluorescent staining for CD68 (red) in conjunction with pan-keratin (green; i), or CD31 (green) and smooth muscle actin-α (SMA; purple; ii).

receptor also commonly used as a marker for macrophages) and CSF1R (Fig 2A). This comparative analysis revealed a lack of correlation in cell density between the three markers. We next evaluated frozen BC tissue sections by confocal microscopy following immunofluorescent detection of CD68 in combination with CSF1R or CD45 (Fig. 2B). While all cells expressing high levels of the CSF1R also expressed CD68, there was a distinct population of CD68+ cells that expressed neither CSF1R, nor CD45. CD68 did not significantly co-localize with keratin+ epithelial cells, CD31+ endothelial cells or smooth muscle actin-α-expressing mural cells surrounding vasculature (Fig. 3C). This contrasted with murine mammary tumors isolated from MMTV-PyMT transgenic mice (7), where CD68+ cells co-expressed both CSF1R and the murine macrophage marker F4/80 (data not shown). In agreement with historic literature (8, 9), these results thus indicate that CD68 is not a macrophage-specific marker in human BC.

STATUS: COMPLETE

Evaluate the phenotype of lymphocyte populations:

Examine expression of activation markers and chemokine receptor expression on lymphocyte populations by flow cytometry. (months 12-24).

To reveal the phenotype of T cells infiltrating BCs, we examined surface marker and chemokine receptor expression of tissue-infiltrating CD4+ and CD8+ T cells (Fig. 3A, B). Specifically, both CD4+ and CD8+ T cells displayed increased expression of activation markers CD69 and HLA-DR compared to peripheral blood T cells, with a corresponding loss of markers for naïve T cells, CD45RA and CCR7. Furthermore, while all T cells constitutively expressed the co-stimulatory receptor CD28 (data not shown), expression of CD27, another co-stimulatory receptor, was reduced in a large proportion of tissue-infiltrating cells, indicative of shedding following interaction with its ligand CD70.
and potential acquisition of effector functions (11, 12). CD4⁺ and CD8⁺ T cells also displayed substantially upregulated expression of chemokine receptors CCR4 and CCR5 (Fig. 3B), and while CD8⁺ T cells constitutively expressed CXCR3, tissue-infiltrating CD4⁺ T cells exhibited higher CXCR3 expression than their counterparts in peripheral blood. Surface marker expression by tissue-infiltrating CD4⁺ and CD8⁺ T cells was subtly different between tumor and benign tissue in some samples; however, these changes were not consistent across patients, or between CTX-naïve and CTX-treated groups (data not shown).

Examine the presence of regulatory T cells through flow cytometry of CD25⁺ cells and FoxP3 immunohistochemistry. (months 12-24).

Despite the apparent reduction in the percentage of CD4⁺ T cells in tumors from CTX-treated patients, the density of IHC detected regulatory T cells expressing FoxP3 (Fig. 4A), specifically expressed by CD3⁺CD4⁺ cells in the tumor (Fig. 4B), was not altered. Gating on CD25⁺ cells, consisting of greater than 80% of FoxP3⁺ cells in all samples tested, also revealed

![Fig. 4. Presence of CD4⁺FoxP3⁺ regulatory T cells within tumors. (A) Number of FoxP3 positive cells per area as determined by automated counting (left) with a representative stained section shown (right). (B) Immunofluorescent staining of tumors for CD4 (green), CD3 (red) and FoxP3 (teal). Arrows indicate CD3⁺CD4⁺FoxP3⁺ (red), CD3⁺CD4⁺FoxP3⁺ (green) and CD3⁺CD4⁺FoxP3⁺ (teal) cells. (C) Percent of CD25⁺ cells within the CD3⁺CD4⁺ T cell population (left panel) with a representative polychromatic dot plot demonstrating FoxP3 staining within this population (right panels). (D) Representative histograms of CD3⁺CD4⁺FoxP3⁺ (red) and CD3⁺CD4⁺FoxP3⁺ cells (blue) showing expression of CD45RO, CD69, CD25, CD127 and HLA-DR.](image-url)
that the relative percentage of these cells was invariant between groups (Fig. 4C). Phenotypically, CD4^{+}FoxP3^{+} cells displayed an activated phenotype with equivalent surface levels of CD45RO and CD69 to CD4^{+}FoxP3^{-} cells, and as has been reported for cells in peripheral blood (13), expressed lower levels of CD127 (Fig. 4D). Interestingly, while not all FoxP3^{+} cells expressed HLA-DR, they did comprise the majority of HLA-DR-expressing CD4^{+} T cells, in addition to coexpressing high levels of CD25.

**STATUS: COMPLETE**

**Compare leukocyte infiltration in patients treated with neoadjuvant chemotherapy:**

Utilize polychromatic flow cytometry to compare relative frequency of myeloid populations, including macrophages, mast cells, neutrophils, basophils, dendritic cells, and eosinophils. (months 12-24)

Comparative analysis of residual BC tissue removed from patients following neoadjuvant CTX revealed an obvious difference in the percentages of myeloid-lineage cells compared to the CTX-naive group. With some exceptions, this included an increased presence of macrophages as a percent of total leukocytes (Fig. 5A), as well as by density evaluation of CSFIR (CSF1R)-positive cells in tissue by IHC (Fig. 5B). Increased percentages of mast cells (Fig. 5C) and neutrophils (Fig. 5D) were also evident in most CTX-treated patients, with an approximate 14-fold increase in CTX-treated versus CTX-naive groups. Basophils (FceR1alpha^{+}CD117^{+}CD11b^{+}CD49d^{+}; Fig. 5E) were highly increased in only one of six CTX-treated samples, while the percentage of myeloid dendritic cells (CD11c^{+}HLA-DR^{+}CD14^{lo}; Fig. 5F) was unchanged. Evaluation of plasmacytoid dendritic cells expressing CD85g/ILT7 detected an insufficient number of events for analysis. Thus, with the exception of basophils, dendritic cells and CD15^{+}CD11b^{+}CD49d^{+} eosinophils – which were present just at a detectable level in the tissues examined – increased presence of myeloid-lineage cells typified residual tumors of women treated with neoadjuvant CTX.
Utilize polychromatic flow cytometry to compare relative frequency of lymphocyte populations, including NK cells, B cells, CD4+ T cells, CD8+ T cells, and γδ T cells. (months 12-24)

While we observed no difference in the percent of CD3εCD56NKG2D+ natural killer (NK) cells (Fig. 6A), higher levels of CD19/CD20+HLA-DR+ B cells were evident in several CTX-naive tumors as compared to both normal tissue and CTX-treated tumors (Fig. 6B). As has been previously reported (14), B cells were clustered together in association with T cells (Fig. 6C). Notably, CD4+ T cells as a percent of the total CD45+ population were also increased in CTX-naive tumors as compared to both normal tissue and residual post-neoadjuvant tumors (Fig. 6D). As the percent of CD8+ T cells was unchanged within the CTX-treated group (Fig. 5E), this

![Fig. 6. Improved cytotoxic T cell response in CTX-treated tumors. (A) CD3εCD56NKG2D+ natural killer cells and (B) CD3εCD19/20+HLA-DR+ B cells shown as a percent of total CD45+ cells as determined by flow cytometry. (C) Immunofluorescent staining of tumors for CD20 (green) and CD3 (red). (D) CD3εCD4+ T cells and (E) CD3εCD8+ T cells shown as a percent of total CD45+ cells. (F) Ratio of CD8+ to CD4+ T cells within CTX-naive versus CTX-treated tumors. Number of CD8-positive (G) and granzyme B-positive (H) cells per area as determined by automated counting. (I) Representative sections stained with CD8 or granzyme B from CTX-naive (left panels) or CTX-treated (right panels) tumors. Red arrows indicate cells displayed in enlarged insets. N, nonadjacent normal; T, tumor.]
resulted in an altered ratio of CD8+ to CD4+ T cells (Fig. 6F). Although it was unclear whether the density of CD8+ cells in CTX-treated residual tumors was increased (Fig. 6G), the number of cells expressing granzyme B was strikingly evident in two of six CTX-treated tumors (Fig. 6H), while minimal granzyme B staining was observed in CTX-naïve tumors, even in areas with high numbers of CD8+ T cells (Fig. 6I).

**STATUS: COMPLETE**

*NEW AIM 4* was initiated in the last 12 months and has resulted in a PNAS manuscript (Ruffell et al., 2011). Please see appendix for attached manuscript.

**NEW AIM 5: EVALUATE DIAGNOSTIC AND THERAPEUTIC APPROACHES TARGETING MACROPHAGES IN MAMMARY ADENOCARCINOMA**

Examine effects of tumor-associated macrophage depletion, via CSF1-CSF1R pathway blockade, on characteristics of tumor progression and/or response to chemotherapy:

Examine effects of chemotherapy (paclitaxel) on the presence of distinct macrophage populations within mammary tumors. *(months 18-30)*

We have already established that the number of TAMs is increased in both human patients that have undergoing neoadjuvant chemotherapy (15), and tumor bearing MMTV-PyMT mice treated with paclitaxel (1). While we have not yet evaluated TAM subsets in chemotherapy treated animals, we have found two distinct subsets of TAMs in normal mammary glands and mammary tumors, distinguishable largely on the basis of MHCII expression (Fig. 7A and 7B). These subpopulations differentially express a variety of other markers (Fig. 7C), but are morphologically similar (Fig. 7D).

Examine effects of CSF1R kinase blockade on distinct macrophage populations, and other leukocyte subtypes in mammary tumors and their pulmonary metastases. *(months 18-30)*

Preliminary analysis of TAM populations following treatment with the CSF1R kinase inhibitor PLX3397 has revealed that MHCIILO TAMs are preferentially lost during treatment (Fig. 8). Intriguingly, a similar phenomenon has recently been reported in mice during gestation, wherein although CSF1R blockade reduces macrophage accumulation in the myometrium during pregnancy, there is a preferential loss of the MHCIILO population (16).

Examine effects of CSF1R small molecule kinase inhibitor in combination with chemotherapy on mammary tumor growth and metastasis. *(months 24-36)*

These studies have not yet initiated.

**STATUS: ONGOING**
Fig. 7. Distinct macrophage subsets in mammary glands and tumors defined by MHCII expression. (A) Flow cytometric profiles of CD45+ cells displaying MHCII and F4/80 expression. (B) Ratio of MHCIIHI to MHCIILO macrophages in mammary glands versus tumors. (C) Expression of various markers as determined through fluorescence measurement via flow cytometry. (D) Cytospins of purified populations stained with β-actin (green) and DAPI (red).
Determine the mechanism by which a reduction in tumor-associated macrophages improves response to chemotherapy:

Examine whether cytotoxic activity of CD8+ T cells is necessary for enhancement of chemotherapy with CSF1-CSFIR targeting. (months 18-30)

Examine whether CSF1-CSFIR targeting alters the vasculature to enhance penetration of chemotherapeutic agents. (months 24-30)

These studies have not yet initiated.

Examine whether CSF1-CSFIR targeting selectively affects different functional subsets of tumor-associated macrophages: ie TH1/TH2, Tie2+, or FoxP3+. (months 30-36)

These studies have not yet initiated.

Identify molecular pathways by which macrophages alter the vasculature or restrict cytotoxic activity. Utilize neutralizing/blocking antibodies to confirm role of these molecules in limiting the response to chemotherapy. (months 30-36)

Gene expression analysis of the individual TAM subsets revealed an array of differences between MHCII\textsuperscript{HI} and MHCII\textsuperscript{LO} TAMs, but most strikingly, found that MHCII\textsuperscript{LO} TAMs expressed higher levels of IL-10 and arginase-1, both of which are established immunosuppressive molecules (Fig. 9). As we have already established that CD8+ T cells are critical for the enhanced response to chemotherapy following blockade of the CSF1-CSFIR pathway, these findings suggest that direct suppression of the T cell response by MHCII\textsuperscript{LO} TAMs may be a critical mediator of the chemoresponse.

STATUS: ONGOING
Evaluate ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) for detection of macrophages within mammary carcinomas by magnetic resonance (MR) imaging:

Examine in vitro uptake of USPIOs by tumor-associated macrophages. (months 18-24)

Following incubation with the iron oxide nanoparticle ferumoxytol, F4/80\(^+\) TAMs demonstrated a markedly decreased signal on T2-weighted MR images, while F4/80\(^-\) cells demonstrated minimal signal changes compared to untreated controls (Fig. 10A). Calculation of changes in relaxation rates (DR) as quantitative measures of the MR signal enhancement corroborated the qualitative findings with significantly higher DR2 data for ferumoxytol-exposed F4/80\(^+\) TAMs compared to ferumoxytol-exposed F4/80\(^-\) cells consisting primarily of carcinoma cells (p>0.05). Determination of iron content in the samples revealed that increased iron uptake was responsible for the observed relaxation rate changes (Fig. 10B).

Since both TAMs and malignant epithelial cells highly express the folate receptor, folate-linked USPIO have been recently developed for "tumor-targeted imaging" (17-19). F4/80\(^+\) TAMs incubated with folate-engrafted P1133 nanoparticles demonstrated significantly stronger visual and quantitative MR signal enhancement as compared to ferumoxytol and P904 (Fig. 10). However, folate-engraftment also lead to significantly increased nanoparticle uptake and MR enhancement of F4/80\(^+\) populations. The P1133-induced signal effect was inhibited by coinubcation with free folic acid to P904 levels, thus indicating that folate-targeting mediates increased USPIO uptake into mammary carcinomas.
Evaluate USPIOs for contrast enhancement within mammary carcinomas. (months 18-30)

We investigated 90-day-old MMTV-PyMT mice (n=16) bearing late-stage mammary adenocarcinomas before and after intravenous injection of ferumoxytol, as well as syngeneic mice with PyMT-derived orthotopic mammary tumors (n=8) (Fig. 11). All tumors demonstrated an initial negative (dark) enhancement on immediate postcontrast T2-weighted MR images, that was most pronounced in the tumor periphery and which increased slowly and gradually up to 1.0-hour (h) post injection (p.i.). This corresponds to an initial blood pool perfusion of USPIO with slow, gradual transendothelial leakage of the nanoparticles into the tumor interstitium (20-23). At 24 h p.i. of ferumoxytol, all tumors demonstrated a persistent signal decline, which was most pronounced in tumor centers (Fig. 11).

Determine whether USPIOs are selectively labeling tumor-associated macrophages and can be used to quantify the level of macrophages within tumors. (months 24-30)

Detection of iron using DAB-enhanced Prussian Blue staining, and immunodetection of CD68+ TAMs in tissue sections of mammary tumors localized ferumoxytol to CD68+ TAMs (Fig 12A). As it was difficult to show selective uptake using DAB-generated contrast due to high background, we also generated ferumoxytol-FITC to show colocalization by immunofluorescence using an Alexa 488 conjugated anti-FITC antibody. As shown in Fig. 12B, ferumoxytol was specifically found within CD68+ TAMs, but not keratin 18-expressing malignant epithelial cells. While ferumoxytol was not found within all TAMs, these results indicate that the MR signal effects on delayed MR images were largely due to TAM-mediated uptake of contrast agent.

STATUS: COMPLETE

#NEW AIM 5 was initiated in the last 6 months based upon our recent publication in Cancer Discovery (DeNardo et al. 2011). The final subaim involving MRI has also been completed and is now published as the cover article in Clinical Cancer Research (Daldrup-Link et al. 2011). Please see appendix for attached papers.
Fig. 10. In vitro MR scans of iron oxide nanoparticle-labeled cells with corresponding quantitative MR signal enhancement and spectrometry data. (A) Axial T2-weighted MR images through test tubes containing F4/80^+ versus F4/80^- cells labeled overnight with Ferumoxytol, P904, P1133 alone or P1133 with free folic acid (FFA). Cells were kept in suspension in ficoll solution and test tubes were placed in a water bath to avoid artifacts by surrounding air (which would cause a dark MR signal). Image parameters: 3 Tesla, SE 2000/60 (TR/TE in ms). (B) Corresponding R2 relaxation rates, i.e. quantitative measures of the MR signal effect, of iron oxide nanoparticle labeled and unlabeled F4 F4/80^+ versus F4/80^- cells, displayed as mean +/- standard deviation from duplicate experiments.
A. In vivo MR imaging

- Precontrast
- 1-h post contrast
- 24-h post contrast

B. In vivo tumor enhancement

![Graph showing tumor enhancement](image)

**Fig. 11.** In vivo MR imaging of iron oxide nanoparticles. (A) T2-weighted SE images of representative mammary tumors in MMTV-PyMT mice prior to (precontrast), 1 hour (h) and 24 h after administration of 0.5 mmol [Fe]/kg of ferumoxytol, P904 or P1133. The iron oxide nanoparticle-based contrast agents cause a negative (dark) signal effect in the tumor tissue on these scans (arrows point to tumors). (B) Quantitation of MR signal enhancement (delta R2 measurement) of mammary tumors in MMTV-PyMT mice before and after iron oxide-nanoparticle administration, displayed as means +/- standard deviation (n=7 mice/group, except P1133+FFA which contained 3 mice). Note that all tumors show a nanoparticle retention at 24 hours, which is most pronounced for the folate-linked nanoparticle P1133.
Fig. 12. Uptake of ferumoxytol by TAMs in vivo. (A) Localization within OCT-embedded mammary tumors of ferumoxytol (iron; black contrast) to CD68⁺ macrophages (green) using phase contrast of DAB staining and confocal microscopy. (B) Localization of ferumoxytol-FITC (green) to CD68⁺ macrophages (red) but not Keratin 18⁺ carcinoma cells (red) within mammary tumors. Scale bars are shown in images.
III. KEY RESEARCH ACCOMPLISHMENTS:

Aim 4: Completed a comprehensive analysis of leukocytic infiltrate in human breast carcinomas, revealing a unique infiltrate compared to murine tumors, and pronounced influx of myeloid cells in tumors exposed to neoadjuvant chemotherapy.

Aim 5: Identified two distinct populations of tumor-associated macrophages in murine mammary tumors that appear to be preferentially affected by the CSF1/CSF1R pathway. Have identified a way to use MR imaging to monitor TAM infiltration, which may prove critical for the proper evaluation of therapies designed to reduce the presence of TAMs within breast tumors.

IV. REPORTABLE OUTCOMES:

Manuscripts:


Abstracts/Posters:


Presentations:

- Life Sciences Institute, Vancouver, BC (July, 2011)
- 7th Internation Symposium on the Intraductal Approach to Breast Cancer (Feb, 2011)

V. CONCLUSION:

It is now clear that infiltrating immune cells profoundly regulate solid tumor development. Diverse populations of cells infiltrate tumor microenvironments and are altered by cancer cells and surrounding stroma in such a way that many of their bioactivities are co-opted to aid growth and/or metastasis of tumors. Out of this realization emerges novel targets for therapy that may impact patient survival, i.e., immune targets regulating primary tumor development, and those regulating metastatic dissemination and growth. It is thus hypothesized that manipulating the
immune response and neutralizing its effect on neoplastic cells represents an efficacious alternative approach to current disease management.

We have now established in both murine models and human patients that exposure to neoadjuvant chemotherapy induces the recruitment of myeloid populations, including tumor-associated macrophages (1, 15). Using the dependency of this population on the CSF1/CSF1R pathway for recruitment to the tumor microenvironment, we have demonstrated that preventing macrophage influx improves the response of transgenic mice to chemotherapy, resulting in lower primary tumor and pulmonary metastatic burden (1). Despite this success, human breast cancers are infiltrated by a wider variety of myeloid populations, for example mast cells, that may share overlapping functions with macrophages but that are not dependent on the CSF1/CSF1R pathway. Identifying common molecular pathways mediating chemoresistance may therefore improve the chance and/or efficacy of clinical translation. Along these lines, preliminary data suggests that CSF1/CSF1R blockage selectively reduces infiltration of a subpopulation of macrophages with enhanced immunosuppressive properties. Identifying the immunosuppressive pathways involved in restricting the response to chemotherapy therefore hold great potential for improving the rate of pathological complete response in patients and prolonging survival.

VI. BIBLIOGRAPHY:


**VII. APPENDICES:**

A. Complete academic Curriculum vitae for Dr. Brian Ruffell

B. Collected publications from months 13-24

BIOGRAPHICAL SKETCH

NAME
Brian Ruffell

POSITION TITLE
Postdoctoral Scholar
University of California, San Francisco

EDUCATION/TRAINING

<table>
<thead>
<tr>
<th>INSTITUTION AND LOCATION</th>
<th>DEGREE (if applicable)</th>
<th>YEAR(s)</th>
<th>FIELD OF STUDY</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of California, San Francisco, CA</td>
<td>n/a</td>
<td>Current</td>
<td>Cancer Immunology</td>
</tr>
<tr>
<td>University of British Columbia, Vancouver, BC</td>
<td>PhD</td>
<td>2008</td>
<td>Immunology</td>
</tr>
<tr>
<td>University of British Columbia, Vancouver, BC</td>
<td>BSc</td>
<td>2001</td>
<td>Cell Biology/Genetics</td>
</tr>
</tbody>
</table>

POSITIONS AND HONORS:

2008 – pres. Postdoctoral Scholar: Department of Pathology, University of California, San Francisco, San Francisco, CA.

2002 - 2008 Graduate Student: Department of Microbiology and Immunology. University of British Columbia, Vancouver, BC, Canada

1997 - 2001 Undergraduate Student: Department of Science. University of British Columbia, Vancouver, BC, Canada

FELLOWSHIPS AND AWARDS:

2009 DOD Breast Cancer Research Program Postdoctoral Award

2006 Heart and Stroke Foundation of Canada Doctoral Research Award

2006 Robert Emmanuel and Mary Day Endowment Award

2005 John Richard Turner Fellowship in Microbiology

2005 Armauer-Hansen Memorial Scholarship

PUBLICATIONS:


**ABSTRACTS:**


**POSTERS:**


6. 18th EORTC-NCI-AACR: Symposium on Molecular Targets and Cancer Therapeutics. Prague, Czech Republic. November 7-10, 2006


**CONFERENCES:**


10. 18th EORTC-NCI-AACR: Symposium on Molecular Targets and Cancer Therapeutics. Prague, Czech Republic. November 7-10, 2006


**ORAL PRESENTATIONS:**

1. Life Sciences Institute, Vancouver, BC (July, 2011)

2. 7th Internation Symposium on the Intraductal Approach to Breast Cancer (Feb, 2011)

3. Pacific Coast Protease Meeting, Borrego Springs, CA (April, 2010)

4. Stanford University School of Medicine, Stanford, CA (Aug, 2009)

5. Dr. Susan Love Research Foundation, Los Angeles, CA (Jan, 2009)

6. Helen Diller Family Comprehensive Cancer Center, San Francisco, CA (June 2008)

7. Deeley Research Centre, Victoria, BC (May, 2008)

8. BC Cancer Research Centre, Vancouver, BC (May, 2008)

9. Life Sciences Institute, Vancouver, BC (Jan, 2008)
Leukocyte composition of human breast cancer

Brian Ruffellab, Alfred Auab, c, Hope S. Rugoab, c, Laura J. Essermanab, c, E. Shelley Hwangab, c, and Lisa M. Coussensab, d

*Department of Pathology and cHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143; and Departments of dMedicine and aSurgery, University of California, San Francisco, CA 94115

Edited by Kornelia Polyak, Dana Farber Cancer Institute, Boston, MA, and accepted by the Editorial Board July 13, 2011 (received for review March 17, 2011)

Retrospective clinical studies have used immune-based biomarkers, alone or in combination, to predict survival outcomes for women with breast cancer (BC); however, the limitations inherent to immunohistochemical analyses prevent comprehensive descriptions of leukocyte infiltrates, as well as evaluation of the functional state of leukocytes in BC stroma. To more fully evaluate this complexity, and to gain insight into immune responses after chemotherapy (CTX), we prospectively evaluated tumor and nonadjacent normal breast tissue from women with BC, who either had or had not received neoadjuvant CTX before surgery. Tissues were evaluated by polychromatic flow cytometry in combination with confocal immunofluorescence and immunohistochemical analysis of tissue sections. These studies revealed that activated T lymphocytes predominate in tumor tissue, whereas myeloid lineage cells are more prominent in “normal” breast tissue. Notably, residual tumors from an unselected group of BC patients treated with neoadjuvant CTX contained increased percentages of infiltrating myeloid cells, accompanied by an increased CD8/CD4 T-cell ratio and higher numbers of granzyme B-expressing cells, compared with tumors removed from patients treated primarily by surgery alone. These data provide an initial evaluation of differences in the immune microenvironment of BC compared with nonadjacent normal tissue and reveal the degree to which CTX may alter the complexity and presence of selective subsets of immune cells in tumors previously treated in the neoadjuvant setting.

S
everal subtypes of CD45 expressing leukocytes infiltrate breast cancer (BC), including CD4+ and CD8+ T cells, CD20+ B cells, and multiple myeloid lineage cells including tumor associated macrophages (TAMs) that are often identified by immunohistochemical (IHC) detection of CD68 (1). High lymphocyte infiltration is associated with increased survival in patients <40 y of age (2) and with a favorable prognosis in subsets of patients whose tumors are also heavily infiltrated by TAMs (3). More specifically, large cohort studies of patients with BC have revealed that the presence of CD68+ cells in tumor tissue correlates with poor prognostic features (4–6), higher tumor grade (7–9), increased angiogenesis (10–13), decreased disease free survival (6, 11, 14, 15), and increased risk for systemic metastasis when assessed in conjunction with endothelial and carcinoma cell markers (16).

The functional significance of specific leukocytes in BC development has been implied based on experimental studies using murine models of mammary carcinogenesis where mice harboring homozygous null mutations in genes specifying leukocyte development or recruitment have been evaluated. In transgenic mice expressing the polyoma virus middle T antigen regulated by the mouse mammary tumor virus promoter (MMTV PyMT mice), progression of mammary carcinomas and metastases to lungs are reduced in mice lacking the colony stimulating factor 1 (csf1) gene, a cytokine critical for macrophage maturation and recruitment (17, 18). TAMs in mammary tumor tissue are often associated with vasculature (19), where their production of VEGF fosters an angiogenic programming of tumor (20, 21), and their production of EGF promotes invasive tumor growth and subsequent metastases (22, 23). Moreover, TAMs regulated by epithelial CSF1 express higher levels of several hypoxia induced genes (iNOS and arginase I) that, in turn, mediate suppression of anti tumor immunity by blocking cytotoxic T cell proliferation and activation (6, 24). Thus, TAM presence and bioactivity within mammary tumors correspond to their clinical activity, further indicating the importance of TAMs, not only in promoting tumor development, but also in suppression of anti tumor immunity.

BC cells isolated from human BC produce high levels of type II helper (Th2) cytokines including IL 4 and IL 13 (25, 26), which are significant in light of studies demonstrating that several protumor activities of TAMs are regulated by IL 4 derived from CD4+ T cells (1, 27). Based on these findings, we recently reported that infiltration by CD68+, CD4+ and CD8+ immune cells in human BC is predictive of overall survival, and that the ratio of CD68 to CD8a mRNA in tumor tissue correlates with complete pathologic response (pCR) in patients undergoing neoadjuvant chemotherapy (CTX) for early stage BC (6). Despite the clear correlation between these specific immune cell types and BC clinical outcome, leukocyte complexity within tumor tissue remains poorly described, with most studies relying on single marker IHC detection. Furthermore, although some studies have examined the effects of CTX on the presence and function of circulating peripheral blood leukocytes (28), data regarding the effect of CTX on tumor infiltrating immune cells are limited (29).

Herein, we evaluated leukocytic infiltrates in breast tissue from predominantly hormone receptor positive patients who had, or had not, received CTX before definitive surgery. In CTX naïve patients, we found that activated T lymphocytes comprised the majority of immune cells within tumors, whereas myeloid lineage cells predominated in nonadjacent normal breast tissue. In contrast, tumors from patients with residual disease after neo adjuvant CTX contained higher levels of infiltrating myeloid cells, with a simultaneous shift away from a Th2 dominated lymphocyte response.

Results
Increased Presence of T Cells in Tumor Tissue. To evaluate the composition of tumor infiltrating leukocytes in human BC, tumors from 20 patients were evaluated by polychromatic flow cytometry and IHC detection of leukocyte lineages in tissue sections as described in Materials and Methods. Nine invasive ductal carcinomas (IDC) and five invasive lobular carcinomas (ILC) mostly histological grade two or three were obtained from patients with no prior exposure to CTX (CTX naïve) at the time of primary surgery for early stage BC, although one patient had received neoadjuvant tamoxifen. Six tumor samples were obtained from patients previously treated with neoadjuvant CTX before resection (CTX treated), consisting entirely of grade two or three IDC. Notably, three of six CTX treated tumors were HER2+naïve positive, compared with only 1 of 14 CTX naïve tumors, whereas both groups contained roughly equal percentages of tumors negative for estrogen, progesterone, and HER2 receptors (triple negative). Details of tumor pathology are outlined in Table S1. Ipsilateral nonadjacent tissue was also obtained from seven CTX naïve and four CTX treated patients

Author contributions: B.R. and L.M.C. designed research; B.R. performed research; A.A., H.S.R., L.J.E., and E.S.H. contributed new reagents/analytic tools; B.R. and L.M.C. analyzed data; and B.R. and L.M.C. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. K.P. is a guest editor invited by the Editorial Board.

1To whom correspondence should be addressed. E-mail: lisa.coussens@ucsf.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1104303108/-/DCSupplemental.
for use as “normal” tissue, in addition to tissues from two con
trolateral prophylactic mastectomies from patients with ipsilat-
eral ductal carcinoma in situ (DCIS).

Immunohistochemical stains of the pan leukocyte marker CD45 were present in both normal and tumor tissue, but with substantially increased density in BC (Fig. 1A). Leukocyte subsets were evaluated by using a combination of lineage markers to identify specific sub populations (Figs. S1 and S2), with the complexity of these pop ulations shown in Fig. 1B as a percentage of the total number of CD45+ cells in each sample. BC tissues from CTX naïve patients contained infiltrates dominated by T lymphocytes (CD3ε+), with minor populations of natural killer cells (CD3ε−CD56+NGK2Dε) and B lymphocytes (CD19/20+HLA DRεCD3ε). In comparison, myeloid lineage cells including macrophages (CD14ε+CD11bε+HLA DRε), mast cells (FceRIαεCD117εCD11bεCD49dε) and neutrophils (CD15εCD11bεCD49dε) were more evident in the normal tissue from these patients. A similar immune profile was observed in breast tissues obtained from the two prophylactic mastectomies (Fig. 1B).

Increased Presence of Myeloid-Lineage Cells in Residual Tumors from Patients Exposed to Neoadjuvant CTX. Comparative analysis of residual BC tissue removed from patients after neoadjuvant CTX revealed an obvious difference in the percentages of myeloid lineage cells compared with the CTX naïve group. With some exceptions, this difference included an increased presence of macrophages as a percent of total leukocytes (Fig. 2A), as well as by density evaluation of CSF1 receptor (CSF1R) positive cells in tissue by IHC (Fig. 2B). Increased percentages of mast cells (Fig. 2C) and neutrophils (Fig. 2D) were also evident in most CTX treated patients, with an ≈14 fold increase in CTX treated versus CTX naïve groups. Basophils (FceRIαεCD117εCD11bεCD49dε; Fig. 2E) were highly increased in only one of six CTX treated samples, whereas the percentage of myeloid dendritic cells (CD11cε+HLA DRεCD14ε+; Fig. 2F) was unchanged. Evaluation of plasmacytoid dendritic cells expressing CD85g/ILT7 detected an insufficient number of events for analysis. Thus, with the exception of baso phils, dendritic cells, and CD15εCD11bεCD49dε+ eosinophils which were present just at a detectable level in the tissues ex amined increased presence of myeloid lineage cells typified residual tumors of women treated with neoadjuvant CTX.

CD68 Is Not a Macrophage-Specific Marker in Human BC. Macroph ages are well established as regulators of murine mammary tumorigenesis (30), where they can represent up to 80% of leukocytes present within late stage mammary carcinomas (1). In human BC, immunoreactivity for CD68 has been used exten sively for identification of macrophages, with CD68ε cell density associated with reduced overall survival (6, 11, 14, 15).

The high number of CD68ε cells reported in the literature, and shown in Fig. 3A, was in contrast to the limited number of CD14ε+CD11bεHLA DRε macrophages observed by flow cytometry in the BC suspensions examined (Figs. 1B and 2A). To understand this discrepancy, we first evaluated CD68 expression in BC tissue sections, compared with CD163 (a hemoglobin scavenger receptor also commonly used as a marker for macrophages) and CSF1R (Fig. 3A). This comparative analysis revealed a lack of correlation in cell density among the three markers. We next evaluated frozen BC tissue sections by confocal microscopy after immunofluorescent detection of CD68 in combination with CSF1R or CD45 (Fig. 3B). Although all cells expressing high lev els of the CSF1R also expressed CD68, there was a distinct pop ulation of CD68ε cells that expressed neither CSF1R nor CD45. CD68 did not significantly colocalize with keratinε epithelial cells, CD3ε+ endothelial cells, or smooth muscle actin ε expressing mural cells surrounding vasculature (Fig. 3C). This expression contrasted with murine mammary tumors isolated from MMTV-PyMT transgenic mice (17), where CD68ε cells coexpressed both CSF1R and the murine macrophage marker F4/80 (Fig. S3). In agreement with historic literature (31, 32), these results thus indicate that CD68 is not a macrophage specific marker in human BC.

Fig. 1. Leukocyte infiltration of human breast tumors. (A) Hematoxylin and eosin (H&E) staining of tissue sections (Left) with representative immunohistochemistry for CD45 (Right) shown for each. (B) Flow cytometric analysis of leukocyte populations within human breast tumors. Results are shown as a percent of total CD45ε cells with markers used to define specific lineages shown below.

Tumor-Infiltrating T Cells Display an Activated Phenotype. To reveal the phenotype of T cells infiltrating BCs, we examined surface marker and chemokine receptor expression of tissue infiltrating CD4ε and CD8ε T cells (Fig. 4A and B). Specifically, both CD4ε and CD8ε T cells displayed increased expression of ac tivation markers CD69 and HLA DR compared with peripheral
blood T cells, with a corresponding loss of markers for naïve T cells, CD45RA, and CCR7. Furthermore, although all T cells constitutively expressed the costimulatory receptor CD28 (Fig. S4A), expression of CD27, another costimulatory receptor, was reduced in a large proportion of tissue infiltrating cells, indicative of shedding after interaction with its ligand CD70 (33) and potential acquisition of effector functions (34, 35). CD4+ and CD8+ T cells also displayed substantially upregulated expression of chemokine receptors CCR4 and CCR5 (Fig. 4B), and although CD8+ T cells constitutively expressed CXCR3, tissue infiltrating CD4+ T cells exhibited higher CXCR3 expression than their counterparts in peripheral blood. Surface marker expression by tissue infiltrating CD4+ and CD8+ T cells was subtly different between tumor and benign tissue in some samples; however, these changes were not consistent across patients, or between CTX naïve and CTX treated groups (Fig. S4B).

**Altered Lymphocyte Balance in Residual Tumors After Neoadjuvant CTX.** Although we observed no difference in the percent of CD3ε−CD56+ NKG2D+ natural killer (NK) cells (Fig. 5A), higher levels of CD19/CD20+HLA DR+ B cells were evident in several CTX naïve tumors compared with both normal tissue and residual postneoadjuvant tumors (Fig. 5B). As the percent of CD8+ T cells was unchanged (Fig. 5E), the lower percentage of CD4+ T cells within the CTX treated group resulted in an increased CD8 to CD4 ratio (Fig. 5F). Although it was unclear whether the density of CD8+ cells in CTX treated residual tumors was increased (Fig. 5G), the number of cells expressing granzyme B was strikingly evident in two of six CTX treated tumors (Fig. 5H), whereas minimal granzyme B staining was observed in CTX naïve tumors, even in areas with high numbers of CD8+ T cells (Fig. 5J).

Despite the reduced percentage of CD4+ T cells in tumors from CTX treated patients, there was no change in the number of IHC detected regulatory T cells expressing FoxP3 (Fig. S5A), which was specifically expressed by CD3ε+CD4+ cells in the tumor (Fig. S5B). Gating on CD25hi cells, consisting of >80% FoxP3+ cells in all samples tested, also revealed that the relative percentage of these cells was invariant between groups (Fig. S5C). Phenotypically, CD4+FoxP3+ cells displayed an activated phenotype with equivalent surface levels of CD45RO and CD69

**Altered Lymphocyte Balance in Residual Tumors After Neoadjuvant CTX.** Although we observed no difference in the percent of CD3ε−CD56+ NKG2D+ natural killer (NK) cells (Fig. 5A), higher levels of CD19/CD20+HLA DR+ B cells were evident in several CTX naïve tumors compared with both normal tissue and residual postneoadjuvant tumors (Fig. 5B). As the percent of CD8+ T cells was unchanged (Fig. 5E), the lower percentage of CD4+ T cells within the CTX treated group resulted in an increased CD8 to CD4 ratio (Fig. 5F). Although it was unclear whether the density of CD8+ cells in CTX treated residual tumors was increased (Fig. 5G), the number of cells expressing granzyme B was strikingly evident in two of six CTX treated tumors (Fig. 5H), whereas minimal granzyme B staining was observed in CTX naïve tumors, even in areas with high numbers of CD8+ T cells (Fig. 5J).
to CD4+FoxP3− cells and, as has been reported for cells in peripheral blood (37), expressed lower levels of CD127 (Fig. S5 D).

Interestingly, although not all FoxP3+ cells expressed HLA DR, they did comprise the majority of HLA DR expressing CD4+ T cells, in addition to coexpressing high levels of CD25.

These data collectively reveal a shift within tumors toward a TH2 type response in BC characterized by increased presence of B cells and CD4+ T cells, in comparison with nonadjacent normal breast tissue. This shift is reversed in tumors obtained from CTX treated patients, with additional evidence of a cytotoxic T cell response through a more favorable CD8/CD4 T cell ratio and increased presence of granzyme B expressing lymphocytes; thus, even residual tumors from patients with a poor response to CTX may contain immune microenvironments that are more favorably skewed towards an anti tumor, TH1 type immune response.

Discussion

Herein, we present a detailed description of leukocyte complexity in BC as evaluated in a cohort of CTX naïve patients with stage 2/3 tumors, compared with patients with significant residual disease after neoadjuvant CTX. T lymphocytes were the major population within both CTX naive and CTX treated tumors, found almost exclusively in an activated state as determined by increased expression of CD69 and chemokine receptors, with simultaneous loss of naïve markers CCR7 and CD45RA. The presence of activation markers, however, does not definitively demonstrate that intratumoral T cells are functionally active. In fact, granzyme B expression was minimal within tumors from CTX naïve patients, suggesting negligible cytotoxic activity by infiltrating CD8+ T cells. In comparison, granzyme B was highly expressed in one third of the CTX treated tumors, suggestive of a more cytotoxic T cell response within some tumors after exposure to CTX.

Importantly, residual tumors from CTX treated patients also contained reduced percentages of B cells and CD4+ T cells. Tumor infiltrating CD4+ T cells in BC are known to express the Th2 cytokines IL 4 and IL 13 concomitantly with the production of IFN γ (25, 26), consistent with coexpression of CXCR3 and CCR4 (38, 39) as we observed herein. It remains to be determined whether cytokine production by CD4+ T cells is altered by neoadjuvant CTX; however, the combined reduction in both CD4+ T cells and B cells is indicative of a favorable shift away from a TH2 microenvironment. This shift could be relevant for TAM function, as has been described in the MMTV PyMT model where TAMs are programmed by IL 4 toward a Th2 phenotype (1), and more recently in pancreatic ductal adenocarcinoma during treatment where an agonist CD40 monoclonal antibody fostered cytolytic macrophage activities (40).

Although the extent of lymphocyte infiltration has been associated with improved prognosis in subsets of patients (2, 3), and with pCR after CTX (41, 42), information regarding the relationship between individual lymphocyte subsets to survival is limited. High FoxP3 counts correlate with reduced overall and relapse free survival in estrogen receptor (ER) positive tumors (43), and pCR to neoadjuvant CTX is associated with reduced FoxP3 grading (44, 45). Although two studies examining T cell infiltration by flow cytometry found conflicting results regarding the CD8:CD4 ratio and lymph node metastasis (46, 47), the number of CD8+ T cells within tissue has been associated with improved patient survival (48). We have also reported a CD68/CD4/CD8 immune signature predicting overall and relapse free survival, with inverse correlations evident for CD4 when used in conjunction with other markers (6). There is thus an urgent need for additional prospective investigations where multiple parameters of lymphocytic infiltration and functionality are evaluated to determine the most significant biomarker comparisons that predict outcome and guide specific therapy.

Fig. 4. Tissue infiltrating T cells display an activated phenotype. (A and B) Representative histograms of CD3+CD4+ (Upper) or CD3+CD8+ (Lower) T cells isolated from a single CTX treated patient with both normal (blue) and tumor (red) tissue. Expression of activation markers CD69 (Left), HLA DR (Center Left), CD45RA (Center Right), and CD27 (Right) are shown in A, and expression of chemokine receptors CCR4 (Left), CCR5 (Center Left), CCR7 (Center Right) and CXCR3 (Right) are shown in B.
Although used successfully in multiple studies to relate TAM infiltration with clinically relevant outcomes, our results indicate that CD68 alone cannot accurately evaluate macrophage presence in human breast tissue given that multiple stromal cells express it and that a subset of these are CSF1R− and CD45 negative. We observed that the nonleukocytic CD68+ cells were predominantly located within tumor stroma and, thus, based on this localization and morphology, we speculate that CSF1R−CD68+ cells likely reflect tumor associated fibroblasts or monocyte derived fibrocytes in agreement with other reports (31, 32, 49 52). Our findings do not invalidate CD68 as a clinically relevant marker and, importantly, CSF1 response gene signatures have been identified in breast adenocarcinomas that are predictive of recurrence risk and metastasis (53, 54). However, given the important role that fibroblasts (and perhaps fibrocytes) play in fostering aspects of tumorigenesis (55 57), differentiating among macrophages, fibroblasts, and other stromal populations within tumors has the potential to improve diagnostic information currently generated by immunodetection of CD68.

As we have reported for expression of csf1 mRNA (6), multiple genes encoding myeloid cell chemoattractants are differentially expressed by human BC cell lines, with variable induction of these genes in response to CTX (Fig. S6). Although differential expression between cell lines corresponding to particular subtypes of BC is evident, it is doubtful these cell lines accurately represent the response of BC tumor tissue; thus, we are investigating whether differences in myeloid cell infiltrates reflect distinct molecular subtypes of BC and to what extent these differ in residual tumors from CTX treated patients.

It is important to acknowledge that leukocyte composition within tumors responding to CTX likely differs substantially from residual or recurrent tumors from patients that have received CTX, given what is known regarding immune responses to CTX induced cell death (28). However, we recently reported that in mammary carcinomas of MMTV PyMT mice, blockade of the CSF1 CSF1R pathway critical for TAM recruitment improved response to CTX through a CD8+ T cell dependent effect (6). Thus, even though the findings presented herein are based on a small dataset of heterogeneous tumor subtypes, and our results may be biased because of sample selection favoring large and/or less CTX responsive tumors among the CTX treated group, the clear distinctions in the myeloid profiles between CTX naive and CTX treated tumors is provocative and indicates that a CSF1 targeted strategy may be a promising approach to enhance therapeutic efficacy of cytotoxic CTX, particularly for treatment of refractory BC. Moreover, given the increase in granulocytic populations within tumors resistant to CTX, and the involvement of these cells in regulating immune responses in chronic inflammatory diseases (58 62), these populations may also be functionally relevant, and targeting common pathways of immune suppression within the tumor microenvironment may provide additional therapeutic opportunities to increase efficacy of neoadjuvant CTX.


Supporting Information

Ruffell et al. 10.1073/pnas.1104303108

SI Materials and Methods

Flow Cytometry. Freshly resected tissue was manually minced and then incubated for 45 min at 37 °C in DMEM (Invitrogen) with 2.0 mg/mL Collagenase A (Roche) and 50 units/mL DNase I (Roche). Single cell suspensions were prepared by filtering through 70 μm nylon strainers (BD Biosciences), and <10^6 cells were incubated for 30 min on ice with Fc Receptor Binding Inhibitor (eBioscience) diluted 1/10 in PBS containing Live Dead Aqua (1:500, Invitrogen). Cells were then incubated for 30 min in PBS containing 1.0 mM EDTA and 5% FCS along with manufacturers’ suggested dilutions of fluorescently labeled primary monoclonal antibodies (Table S2). After washing once, cells were fixed with BD Cytofix for 30 min on ice, washed again, and stored at 4 °C until analysis with an LSRII flow cytometer (BD Bioscience). Before intracellular FoxP3 staining, cells were instead fixed with the FoxP3 Fixation/Permeabilization system (eBioscience) according to the manufacturer’s instructions. Immunohistochemistry. Sections (5 μm) of formalin fixed, paraffin embedded tissues were deparaffinized with xylene, rehydrated, immersed in antigen retrieval citra (Biogenex), then heated for 7 min at maximum power in a microwave, followed by a 30 min incubation in the heated buffer. After washing 3 times in PBS and surrounding tissues with a hydrophobic Super Pap Pen (The Binding Site), peroxidase activity and nonspecific binding was blocked with appropriate components of the Thermo Scientific Ultravision Detection Kit according to the manufacturer’s instructions. After a second blocking step with PBS containing 5% goat serum, 2.5% BSA, and 0.1% Tween 20, unlabeled primary antibodies (Table S3) were diluted according to the manufacturer’s instructions and added to sections overnight at 4 °C. After washing, antibodies were detected by using the appropriate components of the Thermo Scientific Ultravision Detection Kit according to manufacturer’s instructions. After development with liquid DAB, slides were washed in H2O, counterstained according to manufacturer’s instructions. Additional primary antibodies were added overnight at 4 °C in 0.5X blocking buffer, and after washing, slides were incubated with a biotinylated anti mouse or rabbit secondary (Vector Laboratories) for 30 min. The signal from the diluted antibody was then amplified with a TSA indirect kit (Perkin Elmer) according to manufacturer’s instructions. After extensive washing, additional primary antibodies were added overnight at 4 °C. After another round of washing, goat anti mouse Alexa 488, donkey anti rabbit or anti mouse Alexa 546, and streptavidin Alexa 647 (1:500, Invitrogen) were used to detect all three antibodies. To use three primary murine antibodies, slides were blocked with 5.0 μg/mL mouse IgG1 and IgG2a (BioLegend) for 30 min after detection of the first primary antibody with anti mouse Alexa 647. Slides were then incubated with two primary antibodies directly conjugated to either FITC or Cy3 for 3 h, washed, and incubated with goat anti FITC Alexa 488 (Invitrogen). Slides were mounted with ProLong Gold with DAPI (Invitrogen) and images were acquired by using a LSM510 Confocal Laser Scanning Microscope (Carl Zeiss).

Real-Time PCR. Culture and exposure of human BC cell lines to CTX agents was performed as described (1). mRNA was isolated from cells by using the RNeasy mini kit (Qiagen), contaminating DNA was removed by DNase I (Invitrogen) digestion, and reverse transcription into cDNA was performed by using Super Script III (Invitrogen) according to the manufactures’ directions. Real time PCR was performed by using the Taqman system after a preamplification step with TaqMan PreAmp (Applied Bio systems) according to the manufacturer’s instructions.

Fig. S1. Gating strategy for identification of myeloid lineage populations. Starting from the upper left, arrows indicate directionality of subgates. Markers are indicated to the left and bottom of each polychromatic dot plot. Identified populations are marked in red text.
Fig. S2. Gating strategy for identification of lymphocyte populations. Starting from the upper left, arrows indicate directionality of subgates. Markers are indicated to the left and bottom of each polychromatic dot plot. Identified populations are marked in red text.

Fig. S3. Immunofluorescent staining in murine mammary tumors for CD68 (red; i and iii), CSF1R (green; i and ii) or F4/80 (red, ii; green, iii).
Fig. S4. Activation marker expression on T lymphocytes. (A) Representative histograms of CD28 expression for CD3+CD4+ (Upper) or CD3+CD8+ (Lower) T cells isolated from a single CTX treated patient with both normal (blue) and tumor (red) tissue. (B and C) Percent of CD69 expressing (B) or HLA DR expressing (C) T cells from all samples.
Fig. S5. Presence of CD4+FoxP3+ regulatory T cells within tumors. (A) Number of FoxP3 positive cells per area as determined by automated counting (Left) with a representative stained section shown (Right). (B) Immunofluorescent staining of tumors for CD4 (green), CD3 (red), and FoxP3 (teal). Arrows indicate CD3+CD4 FoxP3 (red), CD3+CD4+FoxP3 (green), and CD3+CD4+FoxP3+ (teal) cells. (C) Percent of CD25hi cells within the CD3+CD4+ T cell population (Left) with a representative polychromatic dot plot demonstrating FoxP3 staining within this population (Right). (D) Representative histograms of CD3+CD4+FoxP3+ (red) and CD3+CD4+FoxP3+ cells (blue) showing expression of CD45RO, CD69, CD25, CD127, and HLA DR.
Fig. S6. CTX induces chemokine gene expression changes in human breast cancer cell lines. Relative gene expression compared with untreated controls after in vitro exposure to 25 nM paclitaxel or cisplatin for 24 h. Data represent an average of three replicates. Absence of bars for treated samples indicates undetectable gene expression in control. Fold change of 1× is shown with black horizontal bar, and 2× change is shown with gray horizontal bar.
Table S1. Patient information for evaluated tissue samples. ER, PR, and Her2 status is shown as grade, with percent positivity for ER/PR, and Her2 (evaluated by FISH) shown in parentheses.

<table>
<thead>
<tr>
<th>Age</th>
<th>Histology</th>
<th>Grade</th>
<th>ER</th>
<th>PR</th>
<th>Her2</th>
<th>Tumor size, cm</th>
<th>Node</th>
<th>Neoadjuvant Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>63</td>
<td>IDC</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1.6</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>56</td>
<td>IDC</td>
<td>3</td>
<td>3+</td>
<td>3+</td>
<td>0</td>
<td>2.6</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>57</td>
<td>IDC</td>
<td>2</td>
<td>3+</td>
<td>2+</td>
<td>0</td>
<td>0.9</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>61</td>
<td>IDC</td>
<td>3</td>
<td>3+</td>
<td>2+</td>
<td>1+</td>
<td>4.8</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>78</td>
<td>IDC</td>
<td>3</td>
<td>3+</td>
<td>1+</td>
<td>3+</td>
<td>2.2</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>54</td>
<td>ILC</td>
<td>2</td>
<td>3+</td>
<td>3+</td>
<td>0</td>
<td>7.0</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>78</td>
<td>IDC</td>
<td>3</td>
<td>3+</td>
<td>0</td>
<td>0</td>
<td>2.6</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>55</td>
<td>ILC</td>
<td>3</td>
<td>3+</td>
<td>0</td>
<td>2+</td>
<td>7.3</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>76</td>
<td>IDC</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.9</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>65</td>
<td>IDC</td>
<td>2</td>
<td>3+</td>
<td>3+</td>
<td>0</td>
<td>9.0</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>74</td>
<td>IDC</td>
<td>2</td>
<td>1+</td>
<td>0</td>
<td>0</td>
<td>0.8</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>65</td>
<td>ILC</td>
<td>2</td>
<td>3+</td>
<td>3+</td>
<td>0</td>
<td>1.1</td>
<td>Tamoxifen</td>
<td>None</td>
</tr>
<tr>
<td>59</td>
<td>ILC</td>
<td>2</td>
<td>3+</td>
<td>1+</td>
<td>0</td>
<td>7.0</td>
<td>+</td>
<td>None</td>
</tr>
<tr>
<td>71</td>
<td>ILC</td>
<td>1</td>
<td>3+</td>
<td>0</td>
<td>0</td>
<td>3.0</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>73</td>
<td>IDC</td>
<td>2</td>
<td>3+</td>
<td>3+</td>
<td>3+</td>
<td>9.8 (4.2)</td>
<td>+ (+)</td>
<td>Docetaxel, Carboplatin, Trastuzumab</td>
</tr>
<tr>
<td>66</td>
<td>IDC</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10 (9.6)</td>
<td>+ (+)</td>
<td>Valproic Acid, 5 FU, Epirubicin, Cyclophosphamide</td>
</tr>
<tr>
<td>49</td>
<td>IDC</td>
<td>3</td>
<td>3+</td>
<td>0</td>
<td>2+</td>
<td>4.3 (4.3)</td>
<td>( )</td>
<td>Paclitaxol, Doxorubicin, Cyclophosphamide</td>
</tr>
<tr>
<td>39</td>
<td>IDC</td>
<td>2</td>
<td>3+</td>
<td>0</td>
<td>2+</td>
<td>8.0 (9.9)</td>
<td>+ (+)</td>
<td>Docetaxel, Doxorubicin, Cyclophosphamide</td>
</tr>
<tr>
<td>38</td>
<td>IDC</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>3+</td>
<td>3.5 (9.2)</td>
<td>+ (+)</td>
<td>Doxorubicin, Cyclophosphamide, Trastuzumab, Lapatinib</td>
</tr>
<tr>
<td>51</td>
<td>IDC</td>
<td>3</td>
<td>2+</td>
<td>0</td>
<td>2+</td>
<td>3.9 (4.2)</td>
<td>( )</td>
<td>Valproic Acid, 5 FU, Epirubicin, Anastrozole</td>
</tr>
</tbody>
</table>

Tumor size and node status are shown following neoadjuvant CTX in parentheses.
Table S2. Antibodies used for flow cytometry

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Clone</th>
<th>Fluorophore</th>
<th>Company</th>
<th>Catalog no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3ε</td>
<td>OKT3</td>
<td>PerCP eFluor 710</td>
<td>eBioscience</td>
<td>46 0027 42</td>
</tr>
<tr>
<td>CD3ε</td>
<td>OKT3</td>
<td>PerCP Cy5.5</td>
<td>eBioscience</td>
<td>45 0027 42</td>
</tr>
<tr>
<td>CD4</td>
<td>RPA T4</td>
<td>Qdot 655</td>
<td>Invitrogen</td>
<td>Q10007</td>
</tr>
<tr>
<td>CD4</td>
<td>RPA T4</td>
<td>PE</td>
<td>BioLegend</td>
<td>300508</td>
</tr>
<tr>
<td>CD8α</td>
<td>RPA T8</td>
<td>APC eFluor 780</td>
<td>eBioscience</td>
<td>47 0088 42</td>
</tr>
<tr>
<td>CD8α</td>
<td>RPA T8</td>
<td>Qdot 605</td>
<td>Invitrogen</td>
<td>Q10009</td>
</tr>
<tr>
<td>CD11b</td>
<td>ICRF44</td>
<td>PE Cy7</td>
<td>eBioscience</td>
<td>25 0118 42</td>
</tr>
<tr>
<td>CD11c</td>
<td>3.9</td>
<td>Alexa 700</td>
<td>eBioscience</td>
<td>56 0116 73</td>
</tr>
<tr>
<td>CD14</td>
<td>61D3</td>
<td>Qdot 655</td>
<td>Invitrogen</td>
<td>Q100056</td>
</tr>
<tr>
<td>CD15</td>
<td>W6D3</td>
<td>Alexa 647</td>
<td>BioLegend</td>
<td>323012</td>
</tr>
<tr>
<td>CD19</td>
<td>HIB19</td>
<td>Alexa 700</td>
<td>eBioscience</td>
<td>56 0199 73</td>
</tr>
<tr>
<td>CD19</td>
<td>HIB19</td>
<td>PerCP Cy5.5</td>
<td>eBioscience</td>
<td>45 0199 73</td>
</tr>
<tr>
<td>CD20</td>
<td>2H7</td>
<td>Alexa 700</td>
<td>BioLegend</td>
<td>302322</td>
</tr>
<tr>
<td>CD20</td>
<td>2H7</td>
<td>PerCP Cy5.5</td>
<td>BioLegend</td>
<td>302326</td>
</tr>
<tr>
<td>CD25</td>
<td>BC96</td>
<td>PE Cy5</td>
<td>BioLegend</td>
<td>302608</td>
</tr>
<tr>
<td>CD25</td>
<td>BC96</td>
<td>PE Cy7</td>
<td>eBioscience</td>
<td>25 0259 42</td>
</tr>
<tr>
<td>CD27</td>
<td>Q23</td>
<td>Alexa700</td>
<td>eBioscience</td>
<td>56 0279 73</td>
</tr>
<tr>
<td>CD28</td>
<td>CD28.2</td>
<td>PE Cy7</td>
<td>eBioscience</td>
<td>25 0289 42</td>
</tr>
<tr>
<td>CD45</td>
<td>HI30</td>
<td>Qdot 705</td>
<td>Invitrogen</td>
<td>Q10062</td>
</tr>
<tr>
<td>CD45</td>
<td>HI30</td>
<td>Qdot 780</td>
<td>eBioscience</td>
<td>47 0459 42</td>
</tr>
<tr>
<td>CD45RA</td>
<td>HI100</td>
<td>Qdot 605</td>
<td>Invitrogen</td>
<td>Q10047</td>
</tr>
<tr>
<td>CD45RO</td>
<td>UCHL1</td>
<td>Alexa700</td>
<td>BioLegend</td>
<td>304218</td>
</tr>
<tr>
<td>CD49d</td>
<td>9F10</td>
<td>PE Cy5</td>
<td>BioLegend</td>
<td>304306</td>
</tr>
<tr>
<td>CD56</td>
<td>HCD56</td>
<td>PE Cy5</td>
<td>BioLegend</td>
<td>318308</td>
</tr>
<tr>
<td>CD56</td>
<td>HCD56</td>
<td>PerCP Cy5.5</td>
<td>BioLegend</td>
<td>318322</td>
</tr>
<tr>
<td>CD69</td>
<td>FN50</td>
<td>FITC</td>
<td>eBioscience</td>
<td>11 0699 73</td>
</tr>
<tr>
<td>CD85g</td>
<td>17G10.2</td>
<td>APC</td>
<td>eBioscience</td>
<td>17 5179 42</td>
</tr>
<tr>
<td>CD86</td>
<td>IT2.2</td>
<td>PE Cy5</td>
<td>eBioscience</td>
<td>15 0869 73</td>
</tr>
<tr>
<td>CD117</td>
<td>YB5.88</td>
<td>PE</td>
<td>eBioscience</td>
<td>12 1179 42</td>
</tr>
<tr>
<td>CD127</td>
<td>eBioRDR5</td>
<td>650NC</td>
<td>eBioscience</td>
<td>95 1278 42</td>
</tr>
<tr>
<td>CCR4</td>
<td>TG6</td>
<td>PE Cy7</td>
<td>BioLegend</td>
<td>335405</td>
</tr>
<tr>
<td>CCR5</td>
<td>HEK/1/85a</td>
<td>PE</td>
<td>BioLegend</td>
<td>313708</td>
</tr>
<tr>
<td>CCR7</td>
<td>TG8</td>
<td>Alexa 647</td>
<td>BioLegend</td>
<td>335603</td>
</tr>
<tr>
<td>CXC3</td>
<td>TG1</td>
<td>Alexa 647</td>
<td>BioLegend</td>
<td>334903</td>
</tr>
<tr>
<td>FoxR1</td>
<td>AER 37</td>
<td>FITC</td>
<td>eBioscience</td>
<td>11 5899 73</td>
</tr>
<tr>
<td>FoxP3</td>
<td>PCH101</td>
<td>PE Cy5</td>
<td>eBioscience</td>
<td>15 4776 42</td>
</tr>
<tr>
<td>HLA DR</td>
<td>L243</td>
<td>eFluor450</td>
<td>eBioscience</td>
<td>48 9952 42</td>
</tr>
<tr>
<td>γδ TCR</td>
<td>B1.1</td>
<td>Alexa 647</td>
<td>BioLegend</td>
<td>331214</td>
</tr>
<tr>
<td>Vα24Jα18</td>
<td>6B111</td>
<td>PE</td>
<td>eBioscience</td>
<td>12 5806 42</td>
</tr>
</tbody>
</table>

Table S3. Antibodies used for immunohistochemistry and immunofluorescence

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Species</th>
<th>Dilution</th>
<th>Company</th>
<th>Catalog no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3</td>
<td>Rabbit</td>
<td>1/150</td>
<td>Thermo Scientific</td>
<td>RM 9107 S1</td>
</tr>
<tr>
<td>CD4</td>
<td>Mouse</td>
<td>1/20</td>
<td>Thermo Scientific</td>
<td>MS 1528 S1</td>
</tr>
<tr>
<td>CD8</td>
<td>Mouse</td>
<td>1/100</td>
<td>Thermo Scientific</td>
<td>MS 457 S1</td>
</tr>
<tr>
<td>CD20</td>
<td>Mouse</td>
<td>1/50</td>
<td>Abcam</td>
<td>Ab9475</td>
</tr>
<tr>
<td>CD31 FITC</td>
<td>Mouse</td>
<td>1/10</td>
<td>BioLegend</td>
<td>303104</td>
</tr>
<tr>
<td>CD45</td>
<td>Mouse</td>
<td>1/100</td>
<td>eBioscience</td>
<td>14 0459 82</td>
</tr>
<tr>
<td>CD45 FITC</td>
<td>Mouse</td>
<td>1/10</td>
<td>BioLegend</td>
<td>304003</td>
</tr>
<tr>
<td>CSF1R</td>
<td>Mouse</td>
<td>1/100</td>
<td>Thermo Scientific</td>
<td>MS 397 P</td>
</tr>
<tr>
<td>Pan keratin</td>
<td>Mouse</td>
<td>1/100</td>
<td>Abcam</td>
<td>61137</td>
</tr>
<tr>
<td>HLA DR</td>
<td>Mouse</td>
<td>1/100</td>
<td>Cell Signaling</td>
<td>4523</td>
</tr>
<tr>
<td>Alexa 488</td>
<td>Rabbit</td>
<td>1/100</td>
<td>eBioscience</td>
<td>14 4777 82</td>
</tr>
<tr>
<td>FoxP3</td>
<td>Mouse</td>
<td>1/40</td>
<td>eBioscience</td>
<td>14 4777 82</td>
</tr>
<tr>
<td>Granzyme B</td>
<td>Mouse</td>
<td>1/50</td>
<td>Thermo Scientific</td>
<td>MS 1157 S1</td>
</tr>
</tbody>
</table>
MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles

Heike E. Daldrup-Link, Daniel Golovko, Brian Ruffell, et al.


Updated Version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-10-3420

Cited Articles
This article cites 56 articles, 18 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/17/17/5695.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.
MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles

Heike E. Daldrup-Link1, Daniel Golovko2, Brian Ruffell3, David G. DeNardo3, Rosalinda Castaneda1, Celina Ansari1, Jianghong Rao1, Grigory A. Tikhomirov1, Michael F. Wendland4, Claire Corot5, and Lisa M. Guoussens3

Abstract

Purpose: The presence of tumor associated macrophages (TAM) in breast cancer correlates strongly with poor outcome. The purpose of this study was to develop a clinically applicable, noninvasive diagnostic assay for selective targeting and visualization of TAMs in breast cancer, based on magnetic resonance and clinically applicable iron oxide nanoparticles.

Experimental Design: F4/80 negative mammary carcinoma cells and F4/80 positive TAMs were incubated with iron oxide nanoparticles and were compared with respect to magnetic resonance signal changes and iron uptake. MMTV PyMT transgenic mice harboring mammary carcinomas underwent nanoparticle enhanced magnetic resonance imaging (MRI) up to 1 hour and 24 hours after injection. The tumor enhancement on MRIs was correlated with the presence and location of TAMs and nanoparticles by confocal microscopy.

Results: In vitro studies revealed that iron oxide nanoparticles are preferentially phagocytosed by TAMs but not by malignant tumor cells. In vivo, all tumors showed an initial contrast agent perfusion on immediate postcontrast MRIs with gradual transendothelial leakage into the tumor interstitium. Twenty-four hours after injection, all tumors showed a persistent signal decline on MRIs. TAM depletion via αCSF1 monoclonal antibodies led to significant inhibition of tumor nanoparticle enhancement. Detection of iron using 3,3′diaminobenzidine enhanced Prussian Blue staining, combined with immunodetection of CD68, localized iron oxide nanoparticles to TAMs, showing that the signal effects on delayed MRIs were largely due to TAM mediated uptake of contrast agent.

Conclusion: These data indicate that tumor enhancement with clinically applicable iron oxide nanoparticles may serve as a new biomarker for long-term prognosis, related treatment decisions, and the evaluation of new immune targeted therapies. Clin Cancer Res; 17(17); 5695–704. ©2011 AACR.

Introduction

Although breast cancer has not historically been linked to underlying inflammation or infection, it exhibits tumor associated inflammation marked by infiltration of leukocytes into developing tumors where increases in some leukocyte subsets parallels disease progression (1-3). In the majority of cases, however, the natural immunity to cancer that is present is not protective, but instead fosters progression. Studies in transgenic mouse models of mammary carcinogenesis revealed that tumor associated macrophages (TAM) promote tumor growth and enhance pulmonary metastasis by high level expression of epidermal growth factor (EGF) and activation of EGF regulated signaling in mammary epithelial cells (MEC) critical for invasive tumor growth and metastatic dissemination (4). Histopathologic and flow cytometric evaluations have revealed that TAMs are the most abundant innate immune cell present in murine mammary carcinomas and in human breast cancers (2, 5). TAM presence in several types of human cancer, including breast, correlates with increased vascular density and worse clinical outcome (6-11). A clinically reliable noninvasive in vivo imaging test that could reliably detect and quantify TAMs could be employed as a novel, widely applicable prognostic assay for stratifying individual patients to more aggressive and/or TAM targeted therapies.

Intravenously injected superparamagnetic iron oxide (SPIO) nanoparticles are effective contrast agents for magnetic resonance imaging (MRI). SPIO are phagocytosed by macrophages in various target tissues depending on their particle size and composition. Relatively large SPIO with...
Translational Relevance

The presence of tumor associated macrophages (TAM) in adenocarcinomas correlates strongly with poor outcome in patients with breast cancer. Our data indicate that the Food and Drug Administration (FDA) approved iron oxide nanoparticle compound ferumoxytol (Feraheme) is preferentially phagocytosed by TAMs, but not by neoplastic tumor cells. In vivo, ferumoxytol administration was associated with an initial tumor perfusion, followed by tumor retention and persistent magnetic resonance enhancement at 24 hours after intravenous administration, which correlated with phagocytosed nanoparticles in TAMs. Together, these data indicate that ferumoxytol enhancement may serve as a new biomarker for long term prognosis and related treatment decisions that will support ongoing development of new immune targeted therapies. Since ferumoxytol is FDA approved as an iron supplement, this application is immediately clinically applicable as an imaging approach via an "off label" use.

hydrodynamic diameters in the order of 80 to 150 nm are rapidly phagocytosed by macrophages of the reticuloendothelial system (RES), such as liver, spleen, and bone marrow, whereas ultra small SPIO (USPIO) with diameters of less than 50 nm escape RES phagocytosis to some extent, leading to a prolonged blood pool circulation and accumulation in infiltrated tissues and tumors due to transendothelial leak and macrophage phagocytosis (12-14).

The goal of this study was to utilize novel USPIO to develop an immediately clinically applicable molecular imaging approach for enhanced imaging of TAMs in breast cancer. Our imaging technique relies on the iron supplement ferumoxytol (Feraheme), recently Food and Drug Administration approved for intravenous treatment of iron deficiency in patients (15-17). Ferumoxytol is also a USPIO compound, providing a strong signal effect on MRIs and thus exerting properties of an magnetic resonance contrast agent (18-21). On the basis of these properties, we postulated that ferumoxytol would be phagocytosed by TAMs in breast cancer, thereby enabling selective detection of TAMs on delayed, postperfusion MRIs.

Materials and Methods

Contrast agents

Three USPIO nanoparticle compounds were investigated: (i) Ferumoxytol (Feraheme, AMAG Pharmaceuticals Inc.) is a USPIO nanoparticle applied for intravenous treatment of iron deficiency in patients with impaired renal function (15, 16, 20, 22, 23). Ferumoxytol consists of an iron oxide core and a carboxydextran coating. Ferumoxytol has a mean hydrodynamic diameter of 30 nm, an $r_1$ relaxivity of 38 s$^{-1}$mM$^{-1}$, and an $r_2$ relaxivity of 83 s$^{-1}$mM$^{-1}$ at 0.94 T and at 37°C. Ferumoxytol was conjugated to fluorescein isothiocyanate (FITC; Ferumoxytol FITC) for detection by immunofluorescent microscopy. (ii) P904 (Guerbet Group, Paris, France) is a USPIO compound currently in phase I clinical trials in Europe with plans for global distribution (24-27). P904 consists of an iron oxide core and a hydrophilic coating by a monomeric organic molecule with 20 hydroxyl groups. P904 has a mean hydrodynamic diameter of 21 nm, an $r_1$ of 14 s$^{-1}$mM$^{-1}$, and an $r_2$ relaxivity of 92 s$^{-1}$mM$^{-1}$ at 1.5 T and 37°C. (iii) P1133 (Guerbet) is a preclinical USPIO with potential future clinical development (24). P1133 is based on P904 but also incorporates 8 to 10 folate moieties per nanoparticle in its coating, added via an amino PEG derivative of folic acid coupled on its carboxylic moiety to the carboxylate bearing iron core. P1133 has a mean hydrodynamic diameter of 26 nm, an $r_1$ relaxivity of 12 s$^{-1}$mM$^{-1}$, and an $r_2$ relaxivity of 95 s$^{-1}$mM$^{-1}$ at 1.5 T and 37°C.

Animal model

This study was approved by the animal care and use committees at the respective institutions. MMTV PyMT mice that spontaneously develop multifocal, multiclonal mammary adenocarcinomas were used at 12 to 14 weeks of age (28). Seven animals each received intravenous injections of ferumoxytol, P904, or P1133. Six additional animals received injections of P1133 + free folic acid. Animal age, weight, and tumor size were not significantly different between experimental groups that received different contrast agents ($P > 0.05$). Additional experiments were carried out in 7 postpubertal female FVB/n mice (10-12 weeks), which received injections of 50,000 PyMT derived tumor cells into the right lower mammary fat pad for induction of orthotopic tumors. Three of these animals were treated with anti colony stimulating factor (CSF1) monoclonal antibody (mAb), clone 5A1, purified by the UCSF Hybridoma core using the ATCC hybridoma (PCRL 2702). The animals received an intraperitoneal injection of 2 mg of anti CSF1 mAb, consisting of a 1 mg starting dose followed by 0.5 mg chaser doses on day 5 and 8, and ferumoxytol enhanced MRI on day 9. Three additional animals served as controls and received intraperitoneal injections of PBS at the corresponding time points above, followed by ferumoxytol enhanced MRI. One additional mouse received 3 subquent MRIs at 0, 1, and 24 hours without any contrast agent injection to confirm that tumors did not show any changes in magnetic resonance signal over a 2 day observation period. For all animals, MRI experiments were carried out when mammary tumors reached an approximate size of 1.0 cm.

Macrophage isolation and in vitro labeling

Tumors from MMTV PyMT mice at day 90 to 95, or PyMT orthotopic tumors, were isolated and digested in collagenase and DNase (Roche Applied Sciences), strained over a cell strainer (BD Falcon, BD Biosciences), and incubated with phycoerythrin (PE) conjugated rat anti-mouse F4/80 antibody (clone CI:A3 1, Caltag). Cells were then incubated with anti PE magnetic beads and isolated
over a magnetic column to provide F4/80<sup>+</sup> cells (macrophages and monocytes) and F4/80<sup>-</sup> cell fractions (malignant mammary epithelial cells and other stromal populations). In a previous study, we reported that F4/80<sup>+</sup> cells represent Ly6G<sup>+</sup>Ly6C<sup>-</sup>CD11b<sup>+</sup>F4/80<sup>+</sup> TAMs (2). A total of 4 × 10<sup>6</sup> of both F4/80<sup>+</sup> and F4/80<sup>-</sup> cells were plated onto cell culture dishes in DMEM supplemented with 10% fetal calf serum. Additional samples were incubated with P1133 at a density of 2.35 mmol/kg free folic acid, a dose that corresponds to 10 times the dose of folic acid engrafted onto P1133. Cells were incubated overnight at standard cell culture conditions (37°C, 5% CO<sub>2</sub>). The next day, nonadherent cells were discarded and adherent cells were removed via a cell lifter. Removed cells were washed 3 times in PBS and resuspended in 400 μL of ficoll at a density of 1.07 g/mL and placed into 2.0 mL conical tubes for imaging. Experiments were done in duplicates.

**In vitro cell imaging and data analysis**

For in vitro imaging of nanoparticle loaded cells, a clinical 3T scanner was used (Signa Excite HD, GE Medical Systems) with a standard wrist coil (USA Instruments). Test tubes were immersed in a water bath and a multiecho spin echo sequence was obtained with the following parameters: TE 15, 30, 45, 60 ms, TR 2000 ms, FOV 8 × 8 cm, matrix 256 × 196 pixels, slice thickness 2 mm, and 2 acquisitions. Image processing was done by using MRVision software (MR Vision Co.). T2 relaxation times were calculated assuming a monoexponential signal decay and using nonlinear least square curve fitting on a pixel by pixel basis.

**Determination of cell iron content**

After imaging, cell samples were digested overnight in trypsin and placed in 10% HNO<sub>3</sub>. Inductively coupled plasma optical emission spectroscopy (ICP OES) was done to quantify the iron content per sample (Perkin Elmer).

**In vivo imaging**

Animals were randomly assigned to MRI when their tumor reached a size of approximately 1.0 cm. Imaging of MMTV PyMT mice before and after injection of different nanoparticles was done with a 2 T Omega CSI II magnetic resonance scanner (Bruker Instruments) and imaging of mice before and after anti CSF1 mAb treatment was done with a 1 T desktop magnetic resonance scanner (Aspect M2 Compact High Performance MR System). Animals were anesthetized with isofluorane and placed on a recirculating water warming pad in a dedicated radiofrequency coil for high resolution MRI. A butterfly cannula filled with heparinized saline solution was introduced into the tail vein and left in place. T1, T2, and T2* weighted imaging sequences were obtained with the following parameters: T1 Spin echo (SE): TR 500 ms, TE 12 ms; T2 SE: TR 2000 2500 ms, TE 15, 30, 45, 60 ms (2T), and TE 20, 40, 60, 80 ms (1T); T2* Gradient echo (GE): TR 240 ms, TE 10 ms, flip angle 30 degrees (2T). MRIs were obtained with a field of view (FOV) of 3 × 3 cm (2T) or 6 × 6 cm (1T), a matrix of 128 × 128 or 200 × 200 pixels, and a slice thickness of 1 to 2 mm.

Following precontrast T1, T2, and T2* weighted imaging, 24 PyMT animals received intravenous injections of 0.5 mmol [Fe]/kg ferumoxytol (n = 7), P904 (n = 7), P1133 (n = 7), P1133 + 2.35 mmol/kg free folic acid (100 times the dose of folic acid engrafted onto P1133; n = 3), or P1133 + 0.235 mmol/kg free folic acid (10 times the dose of folic acid engrafted onto P1133; n = 3). Additional tumor-bearing mice after anti CSF1 mAb treatment (n = 3) or controls (n = 3) were injected with 0.5 mmol [Fe]/kg ferumoxytol. After contrast media injection, without repositioning the mouse, 6 subsequent multiecho T2 SE sequences were obtained over the course of an hour, followed by T1 and T2* weighted images. Mice were removed from the scanner, allowed to wake up, and imaged 24 hours later with T1, T2, and T2* weighted sequences. T2 relaxation times of the tumor were calculated based on multiecho SE sequences and converted to R2 relaxation rates (R2 = 1/T2), which is proportional to contrast agent concentration. The relative change in R2 data between pre- and postcontrast MRIs, ΔR2 (%), was determined as a quantitative measure of tumor contrast enhancement.

**Histology**

After the last MRI, at 24 hours postcontrast media injection, mice were sacrificed, and mammary tumors explanted and placed in optimal cutting temperature (OCT) compound on dry ice for histologic processing. Samples were cut onto slides and warmed to room temperature, followed by fixation in 100% ice cold acetone. Some samples were then washed in H<sub>2</sub>O<sub>2</sub>, and iron deposits in the tissue were detected using the Accustain Iron Stain Kit (Sigma Aldrich) according to the manufacturer’s instructions, followed by signal enhancement with Fast 3,3′ diaminobenzidine (DAB, Vector Laboratories) for 2 minutes. After blocking sections with PBS containing 5% goat serum and 2.5% bovine serum albumin (blocking buffer), sections were incubated overnight at 4°C with 0.5× blocking buffer containing either rabbit anti mouse folate receptor α (1:100, Abcam) or rat anti mouse folate receptor β (1:8, kind gift from Prof. Matsuyama, Kagoshima University, Japan; ref. 29). Staining for folate receptor β was enhanced using a biotinylated anti rat secondary antibody (1:200, Vector Laboratories) and the Tyramide Signal Amplification kit (Perkin Elmer). After extensive washing, sections were incubated overnight with FITC conjugated rat anti mouse CD68 (1:50, Serotec), followed by Alexa 488 conjugated goat anti FITC and either Alexa 546 conjugated donkey anti rabbit or Alexa 546 conjugated Streptavidin (1:500, Invitrogen). For detection of Ferumoxytol FITC, sections were stained with rat anti mouse CD68 (1:100, Serotec), washed, and then incubated with a combination of Alexa 546 conjugated donkey anti rat and Alexa 488 conjugated goat anti FITC. All slides were mounted using ProLong Gold with DAPI (Invitrogen) and analyzed using an LSM510 confocal microscope (Zeiss).
Statistics
Statistical analysis comparing the differences of tumor relaxation rates between mice receiving different contrast agents was done with a Wilcoxon rank sum test. A t test was used to determine the significance of differences between different cell samples and differences between age and tumor size of mice. A P value of less than 0.05 was considered significant.

Results

F4/80 positive TAMs phagocytose USPIO in vitro
Following incubation with the iron oxide nanoparticle ferumoxytol, F4/80⁺ TAMs showed a markedly decreased signal on T2 weighted MRIs, whereas F4/80⁻ cells showed minimal signal changes compared with untreated controls (Fig. 1A). Calculation of changes in relaxation rates (ΔR) as quantitative measures of the magnetic resonance signal enhancement (Fig. 1B) corroborated the qualitative findings with significantly higher ΔR2 data for ferumoxytol exposed F4/80⁺ TAMs compared with ferumoxytol exposed F4/80⁻ cells consisting primarily of carcinoma cells (P > 0.05). Determination of iron content in the samples revealed that increased iron uptake was responsible for the observed relaxation rate changes (Fig. 1C).

Since both TAMs and malignant epithelial cells highly express the folate receptor, folate linked USPIO have been recently developed for “tumor targeted imaging” (24, 30, 31). F4/80⁺ TAMs incubated with folate engrafted P1133 nanoparticles showed significantly stronger visual and quantitative magnetic resonance signal enhancement as compared with ferumoxytol and P904 (Fig. 1). However, folate engraftment also leads to significantly increased nanoparticle uptake and magnetic resonance enhancement of F4/80⁻ populations. The P1133 induced signal effect was inhibited by coincubation with free folic acid to P904 levels (Fig. 1), thus indicating that folate targeting mediates increased USPIO uptake in vitro.

Ferumoxytol leads to persistent tumor enhancement on delayed, postperfusion MRIs and corresponds to specific nanoparticle retention in TAMs
We investigated 90 day old MMTV PyMT mice bearing late stage mammary adenocarcinomas before and after intravenous injection of ferumoxytol, as well as syngeneic mice with PyMT derived orthotopic mammary tumors. All tumors showed an initial negative (dark) enhancement on delayed, postperfusion MRIs and corresponds to specific nanoparticle retention in TAMs (Fig. 3A). As it was difficult to show selective uptake using DAB generated signal on T2 weighted MRIs, we obtained additional MRIs of iron oxide nanoparticle labeled cells with corresponding quantitative magnetic resonance signal enhancement and spectrometry data. A, axial T2 weighted MRIs through test tubes containing F4/80⁺ versus F4/80⁻ cells labeled overnight with Ferumoxytol, P904, P1133 alone, or P1133 with free folic acid (FFA). Cells were kept in suspension in ficoll solution and test tubes were placed in a water bath to avoid artifacts by surrounding air (which would cause a dark magnetic resonance signal). Image parameters: 3 Tesla, SE 2000/60 (TR/TE in ms). B, corresponding R2 relaxation rates that quantitatively measure the magnetic resonance signal effect of iron oxide nanoparticle labeled F4/80⁺ versus F4/80⁻ cells, displayed as mean ± SD from duplicate experiments. C, iron content of the same cell samples as shown in B, as determined by ICP OES.

USPIO mediated TAM enhancement on delayed MRIs can be increased by folate receptor targeting of nanoparticles
To determine whether folate receptor targeting could enhance the MRIs, we obtained additional MRIs of localized ferumoxytol to CD68⁺ TAMs (Fig. 3A). As it was difficult to show selective uptake using DAB generated contrast due to high background, we also generated ferumoxytol FITC to show colocalization by immunofluorescence using an Alexa 488 conjugated anti FITC antibody. As shown in Figure 3B, ferumoxytol was specifically found within CD68⁺ TAMs, but not keratin 18 expressing malignant epithelial cells. Although ferumoxytol was not found within all TAMs, these results indicate that the magnetic resonance signal effects on delayed MRIs were largely due to TAM mediated uptake of contrast agent.
MMTV PyMT mice with late stage mammary adenocarcinomas injected with the folate engrafted USPIO P1133, the nontargeted analogue P904, or P1133 plus free folic acid. P1133 and P904 caused a nonspecific tumor perfusion effect on T2 weighted images during the first hour p.i., which was not significantly different as compared with tumor bearing mice injected with ferumoxytol (Fig. 2). Delayed MRIs showed a significantly stronger persistent tumor signal decline at 24 hour p.i. of P1133 compared with ferumoxytol ($P < 0.05$).

In vivo inhibition experiments with free folic acid are limited due to rapid liver uptake and renal elimination of free folic acid (36). Inhibition experiments with free folic acid at a 10 times increased dose as compared with the folate dose delivered with P1133 resulted in a minor, albeit not significant inhibition of the P1133 induced tumor enhancement ($P > 0.05$). Inhibition experiments with higher folic acid doses proved toxic in tumor bearing mice, similar to previous reports (37). However, delayed MRIs showed significantly less tumor enhancement at 24 hour...
p.i. of folate free P904 compared with folate linked P1133 (P < 0.05; Fig. 2). Because P1133 and P904 are chemically identical except for folate engraftment on P1133, this data indicates increased nanoparticle uptake via folate receptor targeting.

We next evaluated TAMs versus epithelial cells for expression of α and β folate receptor in mammary tumors and revealed folate receptor α staining throughout epithelium, with no expression detectable on CD68⁺ TAMs (Fig. 4A). In contrast, expression of folate receptor β was observed exclusively on CD68⁺ cells, although these represented only a portion of the total CD68⁺ TAMs found within tumors (Fig. 4B) and seemed to be primarily associated with vascular and peripheral regions of mammary tumors. Consistent with the MRIs, Prussian Blue staining for iron was more prominent within tumors from mice injected with P1133 compared with P904 or ferumoxytol (Fig. 4C). Furthermore, although some iron staining was observed in areas that did not seem occupied by TAMs (blue arrow), this was minor compared with staining within stromal areas likely enriched with TAMs (red arrow). Thus, while folate engraftment did increase uptake of USPIOs by cells...
other than TAMs, these results indicate that folate modification of USPIOs may still improve their clinical use as evaluators of TAM presence within tumors.

**Ferumoxytol enhanced MRI detects TAM depletion after anti CSF1 mAb treatment**

Imaging data from a control mouse that underwent 3 subsequent MRIs at 0, 1, and 24 hours without any contrast agent injection confirmed that MMTV PyMT tumors do not show any intrinsic changes in magnetic resonance signal within a 2 day observation period. Mice treated with anti CSF1 mAb showed a similar ferumoxytol tumor perfusion effect compared with untreated controls during the first hour after intravenous ferumoxytol injection. However, at 24 hour p.i., anti CSF1 mAb treated tumors showed less magnetic resonance contrast effects and significantly smaller ΔR2 enhancement data compared with untreated controls (Fig. 5A). Corresponding confocal microscopy evaluations confirmed TAM depletion of anti CSF1 mAb treated tumors (Fig. 5B), indicating that ferumoxytol enhanced MRI is related to TAM density.

**Discussion**

Results from this study show that ferumoxytol can be used as a reliable tool to quantitatively monitor macrophage presence in tumors, suggesting that this imaging technique can be readily investigated as a surrogate measure to predict outcomes for patients with breast cancer, and applied to monitor TAM targeted therapies now in clinical trials.
potentiate pulmonary metastasis of mammary adeno carcinomas through enhanced angiogenesis via regulation of VEGF bioavailability and supplying epidermal growth factor (EGF) to mammary epithelium (5, 44), in addition to suppression of protective adaptive immune responses (3, 42, 43, 45, 46). Exuberant macrophage recruitment to breast cancer has been reported to be strongly associated with poor prognosis, both in animal models and in patients (2, 4, 42, 44). Although phagocytic capacity can be altered by in vitro polarization of macrophages, we have no evidence that ferumoxytol uptake corresponds to a particular TAM phenotype. Regardless, aggressive human breast cancers have been reported to contain few (if any) \( T_{cm} \) polarized macrophages (47), and in the MMTV PyMT transgenic model in particular, TAMs are strongly \( T_{cm} \) polarized by interleukin 4 (2).

Ferumoxytol enhancement is a new, noninvasive indicator for TAM tumor infiltration, which may serve as a novel biomarker for breast cancers with poor outcome and may be utilized to stratify tumors with high TAM infiltration for immune targeted therapies. There have been multiple approaches for specific targeting and/or blockade of TAMs for therapeutic purposes (29, 48, 49), some of which are currently in clinical trials based on experimental data showing that genetic, immunologic, or pharmacologic blockade of CSF1, or its receptor (CSF1R), decreases TAM presence in tissues and in experimental solid tumors, correlating with diminished tumor angiogenesis, and reduced primary tumor growth and pulmonary metastasis (50-54). Because these therapies are not cytotoxic, biomarkers of their efficiency at inducing macrophage depletion would be of great clinical benefit. Moreover, since clinical trials of new therapeutic drugs and new combination therapies are expensive and take years to complete, the immediate value and impact of imaging TAMs and/or TAM depletion via MRI would be immense.

We recognize several limitations with this approach. Studies reported herein were done with ferumoxytol doses of 0.5 mmol/kg. Previously described ferumoxytol doses in humans were in the order of 0.035–0.072 mmol/kg (18, 19). Iron oxide nanoparticles are generally applied in higher doses in rodents as opposed to humans to compensate for the relatively shorter blood half life in rodents. However, future clinical applications must show if the currently applied dose in patients is sufficient for TAM detection, or if the dose can be safely increased. Of note, ferumoxytol showed an excellent safety profile in patients (2–4, 42–44). Although phagocytotic capacity associated with poor prognosis, both in animal models and in more than 700 patients (17). Larger superparamagnetic iron oxide nanoparticles (SPIO, diameter >50 nm) provide higher cellular uptake via ex vivo labeling. However, SPIOs are rapidly phagocytosed by macrophages in liver, spleen, and bone marrow and do not reach TAMs in vivo. USPIOs, on the other hand, are not as quickly recognized by the RES and have a longer circulation time, and can therefore leak into tumor interstitium, where they can be phagocytosed by TAMs. Thus, for “in vivo” TAM labeling, USPIOs are advantageous (32, 33).

To the best of our knowledge, this is the first report of utilizing a clinically applicable nanoparticle for TAM detection by MRI. Other investigators have reported TAM detection with nanoparticles that are not clinically applicable, for either MRI (38) or optical imaging (39). In addition, there have been reports of radiotracer based approaches for TAM detection by positron emission tomography (PET; ref. 39). The latter is associated with radiation exposure and therefore not used routinely for breast imaging. MRI, on the other hand, is radiation free, established for breast cancer detection, and integrates near microscopic anatomic resolution, high sensitivity, and excellent soft tissue contrast. Although histologic methods for quantifying TAMs are more precise, they are invasive, limited to one or few observations, and not representative of the whole tumor in the case of biopsies.

Preclinical and clinical evidence indicates that chronic presence of diverse leukocyte subsets within the stroma of breast cancers promotes tumor growth and metastasis (3, 40, 41). TAMs play a significant protumorigenic role in this context by augmenting neoplastic cell survival and motility via elaboration of cytokines, chemokines, pro teases, and reactive oxygen species (3, 4, 42, 43). TAMs also
As shown by our data, an alternative approach to increase the sensitivity of MRI would be to utilize folate engrafted nanoparticles. Although such particles are currently not available for clinical use, precursors of such compounds are currently entering clinical trials and thus folate engrafted derivatives may become clinically available in the future. Folate engraftment enhances nanoparticle uptake via the folate receptor β, which is highly expressed on TAMs (31). Several investigators including us have reported uptake of USPIO and folate engrafted USPIO by neoplastic cells, which may be a confounding variable when aiming for TAM detection (24, 55, 56). However, data presented here reveal that the ferumoxypol and P1133 uptake in malignant epithelial cells is significantly lower as compared with macrophage uptake, leading to negligible interferences of our imaging approach.

In conclusion, we have shown that iron oxide nanoparticle enhanced MRI can be utilized to detect TAMs in a mouse model of mammary carcinogenesis. Ferumoxypol is a clinically available nanoparticle that can be readily applied for TAM imaging in patients with breast cancer via an "off label" use. Macrophage detection may be enhanced by using folate engrafted nanoparticles that may become available for clinical use in the near future. Clinical studies are underway to evaluate these findings in patients.

Disclosure of Potential Conflicts of Interest

C. Corot works for Guerbet Research and provided contrast agents for this study. She was not involved in data analyses. The other authors disclosed no potential conflicts of interest.

Acknowledgments

The authors thank the UCSF Helen Diller Family Comprehensive Cancer Center Laboratory for Cell Analysis and Mouse Pathology shared resource core facilities and members of the Daldrup-Link and Coussens laboratories for critical discussion.

Grant Support

This work was supported by fellowships from the American Cancer Society to D.G. DeNardo and the Department of Defense Breast Cancer Research Program to B. Ruffell, grants from the NIH/NCI (R01CA130980, R01CA135266, R01CA149943, and P50 CA58207), and the Department of Defense (W81XWH-06-1-0416, PR080177) to L.M. Coussens, grants from the NIH/NCI (R01CA40943 and R21CA156124), Bay Area Breast Cancer Specialized Program of Research Excellence (P50 CA 58207), and a pilot grant from the Sanford Center for Cancer Nanotechnology Excellence and Translation (CCNE-T; NIH/NCI U54 CA151459) to H.E. Daldrup-Link, and grant P50 CA114747 to J. Rao.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 23, 2010; revised July 12, 2011; accepted July 14, 2011; published OnlineFirst July 26, 2011.

References


Immune-regulated pathways influence multiple aspects of cancer development. In this article, we demonstrate that both macrophage abundance and T-cell abundance in breast cancer represent prognostic indicators for recurrence-free and overall survival. We provide evidence that response to chemotherapy is in part regulated by these leukocytes; cytotoxic therapies induce mammary epithelial cells to produce monocyte/macrophage recruitment factors, including colony stimulating factor 1 (CSF1) and interleukin-34, which together enhance CSF1 receptor (CSF1R)-dependent macrophage infiltration. Blockade of macrophage recruitment with CSF1R-signaling antagonists, in combination with paclitaxel, improved survival of mammary tumor-bearing mice by slowing primary tumor development and reducing pulmonary metastasis. These improved aspects of mammary carcinogenesis were accompanied by decreased vessel density and appearance of antitumor immune programs fostering tumor suppression in a CD8+ T-cell-dependent manner. These data provide a rationale for targeting macrophage recruitment/response pathways, notably CSF1R, in combination with cytotoxic therapy, and identification of a breast cancer population likely to benefit from this novel therapeutic approach.

**SIGNIFICANCE:** These findings reveal that response to chemotherapy is in part regulated by the tumor immune microenvironment and that common cytotoxic drugs induce neoplastic cells to produce monocyte/macrophage recruitment factors, which in turn enhance macrophage infiltration into mammary adenocarcinomas. Blockade of pathways mediating macrophage recruitment, in combination with chemotherapy, significantly decreases primary tumor progression, reduces metastasis, and improves survival by CD8+ T-cell-dependent mechanisms, thus indicating that the immune microenvironment of tumors can be reprogrammed to instead foster antitumor immunity and improve response to cytotoxic therapy. Cancer Discovery; 1(1); 54-67. ©2011 AACR

Authors' Affiliations: 1Departments of Pathology, 2Radiation Oncology, 3Medicine, and 4Surgery, and 5Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; 6University College Dublin School of Biomolecular and Biomedical Science, University College Dublin Conway Institute, Belfield; and 7National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin, Ireland; 8Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden; and 9Plexxikon Inc., Berkeley, California

Current affiliation for Dr. DeNardo: Department of Medicine, Washington University, St. Louis, Missouri

Note: Supplementary data for this article are available at Cancer Discovery Online (http://www.aacrjournals.org).

Corresponding Author: Lisa M. Coussens, Department of Pathology, University of California, San Francisco, 513 Parnassus Avenue, HSW450C, San Francisco, CA 94143. Phone: 415-502-6318; Fax: 415-514-0678; E-mail: Lisa.Coussens@ucsf.edu
doi:10.1158/2159-8274.CD-10-0028

©2011 American Association for Cancer Research.
INTRODUCTION

Tumor-associated macrophages (TAM) have been identified as regulators of solid tumor development based on their capacity to enhance angiogenic, invasive, and metastatic programming of neoplastic tissue (1, 2). Colony stimulating factor-1 (CSF1) is a key cytokine involved in recruitment and activation of tissue macrophages, exerting these effects through binding to a high-affinity receptor tyrosine kinase, the cFMS/CSF1 receptor (CSF1R; ref. 3). A second CSF1R ligand, interleukin 34 (IL-34), possesses similar binding affinities and regulates macrophage recruitment to tissues, but exhibits distinct tissue distribution characteristics (4).

Macrophage presence in several types of human cancer, including breast, ovarian, non-small cell lung cancer, and Hodgkin’s lymphoma, correlates not only with increased vascular density but also with a worse clinical outcome (1, 5, 6). Accordingly, a CSF1-response gene signature was identified in human breast cancer that predicts risk of recurrence and metastasis, and is similarly predictive for clinical outcome in colon cancer and leiomyosarcoma (7-9).

On the basis of these findings, it seems reasonable to postulate that blockade of the molecular programs enhancing macrophage recruitment or protumor bioactivity in tumors may represent tractable targets for anticancer therapy. Accordingly, genetic or pharmacologic blockade of CSF1 or its receptor has been reported to decrease macrophage presence in tissues and in some experimental solid tumors, correlating with diminished tumor angiogenesis, reduced primary tumor growth, and pulmonary metastases (1, 2).

Experimental studies have recently revealed that B and T lymphocytes can exert protumor activity indirectly by regulating the bioactivity of myeloid cells, including macrophages, monocytes, and mast cells, resulting in resistance to endocrine therapies and development of metastasis (10-13). We reported that in the absence of a significant CD8+ CTL response, CD4+ T-effector lymphocytes potentiate mammary adenocarcinoma metastasis by directly enhancing the protumor bioactivity of TAMs (11). On the basis of these results, we hypothesized that human breast cancers containing leukocytic infiltrates dominated by CD4+ T lymphocytes and CD68+ macrophages, without significant CD8+ T-cell infiltration, would have a higher relative risk for metastasis and therefore reduced overall survival (OS) of patients. In this article, we report on an immune signature consisting of CD68hi/CD45hi/CD8lo that significantly correlates with reduced OS for patients with breast cancer. Moreover, to demonstrate the biologic significance of this signature, we investigated a combination of standard-of-care chemotherapy and agents that block TAM infiltration of mammary tumors in an aggressive transgenic mouse model of mammary adenocarcinoma development [MMTV-polyoma middle T (PyMT) mice; ref. 14], in which late-stage carcinogenesis and pulmonary metastasis are regulated by CSF1 and tissue macrophages (15). We found that when TAM presence in mammary adenocarcinomas was minimized, antitumor immunity and CD8+ CTL infiltration were enhanced; together, this improved chemosensitivity and resulted in reduced primary tumor development, significant decrease in pulmonary metastases, and improved OS, when compared with treatment using standard chemotherapy alone.

RESULTS

Single Immune Marker Analysis of Leukocyte Infiltration Predicts Breast Cancer Survival

In previous studies, we demonstrated that in the absence of a significant CD8+ CTL response, CD4+ T lymphocytes indirectly promoted invasion and metastasis of mammary adenocarcinomas by directly regulating the protumor bioactivities of TAMs (11). From these data, we predicted that infiltration of primary human breast cancer by CD4+ and CD8+ T lymphocytes and CD68+ macrophages would correlate with aspects of breast cancer regulating OS. To address this issue, we analyzed CD4+, CD8+, and CD68+ leukocyte density in tissue microarrays consisting of tumor tissue obtained at the time of primary surgery from 179 treatment-naïve breast cancer patients (Fig. 1A). We employed a fully automated nuclear algorithm to quantify CD4+, CD8+, and CD68+ cells following immunohistochemical (IHC) detection. For survival analyses, high and low thresholds for each marker were established using a classification and regression decision tree analysis with 10-fold cross-validation (16). Kaplan-Meier analyses indicated that, as single variables, “high” CD4+ T-cell density (P = 0.032) and “low” CD8+ T-cell density (P = 0.012) correlated with reduced OS, whereas CD68+ cell density alone showed no statistical significance (Fig. 1B). However, analysis of CD68+ and CD8+ immune cell infiltration demonstrated an inverse association between stromal infiltration by CD68+ macrophages and CD8+ T lymphocytes in human breast cancer tissues (Spearman’s rho, -0.38; P < 0.001; Supplementary Table S1).

Three-Marker Immune Signature Is Prognostic for Breast Cancer Survival

Heterotypic interactions between diverse leukocyte populations often determine the outcome of immune responses in tissues (17). As such, we proposed that combined analysis of CD4, CD8, and CD68 would allow for improved prognostic stratification of breast cancer patients by assessing both antitumor immunity (i.e., CD8+ density) and protumor immunity (i.e., high CD4+ and CD68+ leukocyte density). Thus, we predicted that an immune profile characterized by CD68hi/CD45hi/CD8lo would represent primary breast cancer controlled by local resection, with improved OS and relapse-free survival (RFS). In contrast, an immune response characterized by CD68lo/CD45hi/CD8hi would instead represent a population of patients at risk for distant metastasis and thus reduced OS. A classification and regression tree algorithm was used to define the signature in the screening cohort (Cohort 1, n = 179; Supplementary Fig. S1). High and low thresholds for each marker were established by decision tree analysis with 10-fold cross-validation.
Figure 1. CD68/CD4/CD8 immune signature is an independent prognostic indicator of breast cancer survival. A, high-magnification images (40×; 80× for inlays) of human breast cancer tissue sections showing immunoreactivity for representative CD68, CD4, and CD8 leukocyte infiltration. B, automated analysis of CD68, CD4, and CD8 immune cell detection, revealing relationship between leukocyte density and OS. Kaplan-Meier estimate of OS comparing auto-score leukocyte high- and low-infiltration groups is shown; 179 samples from Cohort I were used for analyses, and log-rank (Mantel-Cox) P values are denoted for difference in OS. C and D, Kaplan-Meier estimate of RFS comparing CD68<sup>hi</sup>/CD4<sup>hi</sup>/CD8<sup>lo</sup> and CD68<sup>lo</sup>/CD4<sup>hi</sup>/CD8<sup>hi</sup> immune profiles as assigned by random forest clustering to identify optimal thresholds using Cohort I (C). Identified CD68<sup>hi</sup>/CD4<sup>hi</sup>/CD8<sup>lo</sup> and CD68<sup>lo</sup>/CD4<sup>hi</sup>/CD8<sup>hi</sup> immune profiles were used to stratify a second independent cohort, Cohort II (D). Cohort I (n = 179) and Cohort II (n = 498) samples were assessed, and the log-rank (Mantel-Cox) P value is denoted for difference in RFS. E and F, results from multivariate Cox regression analysis of RFS for the CD68/CD4/CD8 signature in Cohort I (E) and Cohort II (F). Hazard ratios (HR) and P values are shown for all characteristics. G and H, RFS in node-positive breast cancer predicted by CD68/CD4/CD8 immune signature. Kaplan-Meier estimates of RFS comparing CD68<sup>hi</sup>/CD4<sup>hi</sup>/CD8<sup>lo</sup> and CD68<sup>lo</sup>/CD4<sup>hi</sup>/CD8<sup>hi</sup> immune profiles as assigned by random forest clustering of breast cancer tissues, breast cancers were stratified into node-negative (G) and node-positive (H) patients and analyzed for RFS. The log-rank (Mantel-Cox) P value is denoted for difference in RFS.

Three-Marker Immune Signature Is an Independent Predictor of RFS in Node-Positive Patients

The OS of breast cancer patients is greatly reduced if metastasis to regional or draining lymph nodes is present at the time of primary tumor detection. Therefore, node-positive patients require aggressive treatment with neoadjuvant or adjuvant systemic chemotherapy, or targeted therapies such as anti-estrogens or trastuzumab. To assess whether immune infiltration by macrophages and T lymphocytes affected the survival of this high-risk group, we examined the impact of the CD68/CD4/CD8 signature following stratification for nodal status. Whereas the CD68/CD4/CD8 signature was not predictive in node-negative patients (Fig. 1G), Kaplan-Meier analysis of Cohort II demonstrated significantly reduced RFS in node-positive patients whose tumors harbored the CD68<sup>hi</sup>/CD4<sup>hi</sup>/CD8<sup>lo</sup> signature.
Macrophages Regulate Response to Chemotherapy

Cytotoxic Therapies Induce TAM Recruitment and CSF1 and IL-34 Cytokine Expression

These findings led us to hypothesize that blocking TAM infiltration in breast cancer patients bearing the CD68<sup>high</sup>/CD4<sup>high</sup>/CD8<sup>low</sup> signature might enhance antitumor T-cell responses and facilitate CD8<sup>+</sup> CTL infiltration and/or re-polarization of CD4<sup>+</sup> T-cell responses toward T-helper 1 cell (TH1). Consistent with this hypothesis, we found an inverse association between stromal infiltration by CD68<sup>+</sup> macrophages and CD8<sup>+</sup> T lymphocytes in human breast cancer tissues (Spearman’s rho, -0.38; P < 0.001; Supplementary Table S1). On the basis of this observation, we postulated that chemoresistance might in part be regulated by TAM and/or CD8<sup>+</sup> T-cell presence in breast cancer tissue. To address this, we initially evaluated leukocyte infiltration in a small cohort of freshly isolated breast tumors from women who had received neoadjuvant chemotherapy, compared with those undergoing primary surgery without preoperative treatment (Supplementary Table S7). We found a higher percentage of CD45<sup>+</sup>CD11b<sup>+</sup>CD14<sup>+</sup> macrophages in breast cancer from women who had received neoadjuvant chemotherapy than in tumors from women treated with surgery alone (Fig. 2A). In contrast, we observed no difference in tumor-infiltrating CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> T lymphocytes between the 2 groups (Supplementary Fig. S3A).

To determine whether TAM presence in breast cancers was directly enhanced by chemotherapy, we evaluated leukocyte responses in MMTV-PyMT mice, a transgenic mouse model of mammary carcinogenesis, following treatment with paclitaxel (PTX; Supplementary Fig. S4). We found that infiltration of mammary tumors by CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>low</sup>Ly6C<sup>+</sup>F4/80<sup>+</sup> TAMs was significantly increased following PTX treatment, with no significant change in the presence of CD3<sup>+</sup>CD8<sup>+</sup> T lymphocytes (Fig. 2B, Supplementary Fig. S3B). Similar PTX-induced TAM recruitment was observed in syngeneic orthotopic PyMT-derived tumors (Supplementary Fig. S3C).

Consistent with our hypothesis, PTX treatment of MMTV-PyMT mice only modestly slowed primary tumor growth (Fig. 2B). For studies herein, we defined TAMs as CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>+</sup>F4/80<sup>+</sup>, monocytic immature myeloid cells (iMC) as CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>+</sup>, and granulocytic iMCs/neutrophils as CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>+</sup> (Supplementary Fig. SSA and B), in agreement with previously published studies (18, 19).

To reveal molecular mediators involved in regulating PTX-induced TAM recruitment, we examined mRNA expression of several monocyte/macrophage cytokines and chemokines in murine mammary epithelial carcinoma cells (MEC) following exposure to several forms of cytotoxic therapy in vitro. CSF1, CCL8/MCP2, and IL34 mRNAs were increased in MMTV-PyMT-derived MECs following exposure to PTX (Fig. 2C). Of these, CSF1 and IL34 mRNAs were also increased following exposure to either CDDP or ionizing radiation (Fig. 2D; Supplementary Fig. S3D). Increased mRNA expression was not merely a response of malignant PyMT-derived MECs (pMEC), because a similar induction was also observed in nontransgenic MECs exposed to PTX in culture (Fig. S3B). Similarly, CSF1 mRNA expression was also induced by PTX and CDDP in 5 of 6 human breast cancer cell lines reflecting the major subtypes of breast cancer (Fig. 2B). In vivo, CSF1 mRNA was increased in mammary tissue of MMTV-PyMT mice following treatment with either PTX or ionizing radiation (Fig. 2F; Supplementary Fig. S3F). Together, these data indicate that induction of CSF1 (and IL34) mRNA and subsequent TAM recruitment into mammary tissue represent a common response of MECs to cytotoxic agents.

Blockade of Chemotherapy-Induced TAM Recruitment

To determine whether tumor-infiltrating TAMs also regulate sensitivity of MECs to cytotoxic therapy, we blocked TAM infiltration in vivo with immunologic and pharmacologic agents (Supplementary Fig. S4) and evaluated myeloid cell infiltration of tumors from treated mice (Supplementary Fig. S5). Mice bearing orthotopic mammary tumors were treated with neutralizing monoclonal antibodies (mAb) CSF1 (clone 551) or CD11b (clone M1/70), or a competitive ATP inhibitor with potent (nM) specificity for CSF1 and cKIT receptor tyrosine kinases (PLX3397), either as a monotherapy or in combination with PTX. CD11b is an integrin cell adhesion molecule expressed on granulocytes, macrophages, monocytes, dendritic cells (DC), and natural killer cells that in part regulates transendothelial migration of cells into tissue and tumor parenchyma. PLX3397 has 10- to 100-fold selectivity for cKIT and CSF1R, as opposed to other related kinases, such as KDR (see Supplementary Fig. S6A and Methods; ref. 20).

Fluorescence-activated cell sorting analysis of the predominant myeloid subtypes infiltrating malignant PyMT-derived tumors revealed that either as a monotherapy, or in combination with PTX, CD45<sup>+</sup>CD11b<sup>+</sup>Ly6C<sup>+</sup>Ly6G<sup>-</sup>F4/80<sup>-</sup> TAM recruitment was significantly diminished following treatment with either αCSF1 mAb or PLX3397, with no effect on infiltration of CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup>iMCs or CD45<sup>+</sup>CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>-</sup>Ly6C<sup>-</sup>MHCII<sup>+</sup>DCs (Fig. 3A and B; Supplementary Fig. SSA and B). Treatment with aCD11b mAb decreased both TAM and iMC infiltration (Fig. 3A). Analysis of the maturation and differentiation status of TAMs remaining in mammary tumor tissue following CSF1 or PLX3397 treatment revealed no significant change in CD11b, CD11c, F4/80, CD45, or MHCII expression (Supplementary Fig. S5B). However, examination of mammary tumor sections revealed a population of perivascular CSF1-independent F4/80<sup>+</sup> TAMs remaining (Fig. 3C). Blockade of TAM recruitment was a direct effect of CSF1/CSFIR blockade: in vitro CSFIR inhibition efficiently blocked CD11b<sup>+</sup> monocyte chemotaxis in response to control or PTX-treated pMEC-conditioned medium, with no effect on chemotaxis of CD3<sup>+</sup> T lymphocytes (Fig. 3D; Supplementary Fig. S3G). These results were mirrored in vivo; treatment of late-stage MMTV-PyMT mice with PLX3397 significantly inhibited both steady-state and PTX-induced tumor infiltration by CD45<sup>+</sup>CD11b<sup>+</sup>Ly6C<sup>-</sup>Ly6G<sup>-</sup>F4/80<sup>+</sup> TAMs (Fig. 3E; Supplementary Fig. S5) without altering TAM maturation/differentiation (Supplementary Fig. S6B).
Figure 2. Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. A, macrophage percentage in fresh primary breast cancer tissues, depicted as mean of CD45^+CD11b^+CD1^+ macrophages as a percentage of total cells (analyzed by flow cytometry). "Neo-adjvant" denotes patients who received chemotherapy prior to surgical excision of their primary breast cancer, as opposed to those who did not, denoted as "untreated". Statistical significance (P < 0.001) between the two groups. B, PTX-induced CSF1 mRNA expression regulates tumor infiltration of macrophages and limits PTX response. LAM percentage in mammary tumors of MMTV-PyMT mice following PTX treatment with mean number of CD45^+CD11b^+CD1^+ MDMs as a percentage of total cells (analyzed by flow cytometry). (i) Primary tumor growth reduced by treatment with PTX. The 85% reduction in MMTV-PyMT tumor volume was assessed every 5 days until endpoint. Treatment schedule is depicted at top, and data are displayed as mean tumor burden ± SEM. Statistical significance between controls and PTX-treated mice (≥8 mice/group). C, expression of monocyte/macrophage chemoattractants following chemotherapy. Quantitative reverse transcriptase PCR (qRT-PCR) analyses of CSF1, MCP1, MCP2, MCP3, and IL-34 expression in MMTV-PyMT-derived tumors treated with PTX for 24 hours in vivo, expressed as mean fold change, compared with controls. Samples were assayed in triplicate for each tested condition. Statistically significant differences between control and PTX-treated groups. D, Dose-dependent expression of CSF1 following chemotherapy and radiation therapy. qRT-PCR analysis of mRNA expression in MMTV-PyMT-derived tumors after treatment with either cisplatin (CDPP) or PTX. A single dose of irradiation, expressed as mean fold change, compared with control ± SEM. Drug and radiation doses are shown. Samples were assayed in triplicate for each tested condition. Statistical significance between control and the indicated treatment. E, CSF1 expression induced by chemotherapy and radiation therapy in human breast carcinoma cell lines. qRT-PCR analysis of mRNA expression in BT474, MDA-MB-435, SK-BR-3, T47D, MCF7, and MDA-MB-231 at 24 hours after treatment with either cisplatin or PTX, expressed as mean fold change, compared with vehicle-treated cells ± SEM. Chemotherapeutic doses are denoted. Samples were assayed in triplicate for each condition. Statistical significance between control and the indicated treatment. F, CSF1 expression induced by chemotherapy and radiation therapy in MMTV-PyMT mammary tumors from mice treated with either PTX (10 mg/kg) every 5 days, or irradiation (single dose of 8 Gy), expressed as mean fold change, compared with vehicle-treated mice (4 mice/group). SE is depicted; statistical significance (P < 0.05; Mann-Whitney) for all gene expression analyses (C-F).

We next treated 80-day-old MMTV-PyMT mice, or mice bearing syngeneic orthotopic PyMT-derived tumors (~1 cm) with eCSF1, eCD11b, or PLX3397 (vs controls) for 5 days, followed by 4 cycles of PTX (10 mg/kg, i.v.; Supplementary Fig. S4). Primary tumor burden at study endpoints (2.0 cm primary tumors or 100 days of age) was significantly reduced in mice treated with combined eCSF1+PTX, eCD11b+PTX, or PLX3397+PTX therapy, compared to mice treated with these as single agents (Fig. 4A and B; Supplementary Figs. S7A). Similar results were observed in syngeneic mice bearing orthotopic PyMT-derived mammary tumors receiving combined PLX3397+carboplatin (CBDCA) therapy (Fig. 4B).

Mammary tumors in MMTV-PyMT mice progress through well-defined stages of cancer development, similar to progression of breast cancer in women, including tissue with florid ductal hyperplasia, ductal carcinoma in situ with early stromal invasion, and poorly differentiated invasive ductal carcinoma (15, 21). Using this staging criterion, we observed that mammary tumors arising in MMTV-PyMT mice treated with combined PLX3397+PTX therapy exhibited decreased development of late-stage carcinoma, compared with tumors in age-matched mice treated with either PTX or PLX3397 as monotherapy (Fig. 4C; Supplementary Fig. S7B). Moreover, the late-stage carcinomas that did develop in PLX3397+PTX-treated mice contained large areas of necrosis (Supplementary Fig. S7C) characterized by increased presence of apoptotic cells, as measured by cleaved caspase 3-positivity (Fig. 4D) with no accompanying change in epithelial proliferation (Supplementary Fig. S7D).

Decreased vascular density accompanies improved chemosensitivity

It is known that TAMs provide VEGF to developing mammary tumors and thereby regulate angiogenic programming of tissue (22-24). Chemosensitivity to CDPP in MMTV-PyMT mice is in part regulated by myeloid-derived VEGF (25); thus, we sought to determine if TAM depletion altered VEGF expression and/
or density of CD31⁺ vessels in MMTV-PyMT mice treated with PTX. Whereas total VEGF mRNA expression was significantly reduced by PLX3397 (Fig. 4E), this 70% reduction did not correlate with a change in vascular density (Fig. 4F). In contrast, combined PLX3397/PTX therapy resulted in a significant reduction in CD31⁺ vessel density within mammary tumors, paralleling induction of apoptosis and necrosis (Fig. 4F).

CSF1-Signaling Blockade Enhances Antitumor Immunity and CTL Infiltration in Response to Chemotherapy

Because analysis of human breast cancer tissues revealed that high stromal TAM density inversely correlated with CD8⁺ T-cell infiltration (Supplementary Table S1), we predicted that depletion of TAMs would enhance CD8⁺ CTL infiltration and thereby foster an antitumor immune microenvironment. Analyses of tumor-infiltrating T lymphocytes in mice treated with αCSF1/PTX or PLX3397/PTX by flow cytometry or IHC revealed significantly increased presence of CD4⁺ and CD8⁺ T cells in mammary tumors (Fig. 5A and B; Supplementary Fig. S8A). Consistent with these findings, cytokine mRNA expression in mammary tissue derived from PLX3397/PTX-treated MMTV-PyMT mice revealed increased mRNA expression of cytotoxic effector molecules, including IFN-γ, granzyme A, granzyme B, perforin-1, and the type 1 DC effector molecules IL-23p40 and IFN-α (Fig. 5C). In contrast, expression of the immunosuppressive molecule arginase-1 was reduced by αCD11b neutralizing antibodies (Fig. 5D).

Figure 3. Cytotoxic therapy induces CSF1-dependent macrophage recruitment. A, analysis of TAM depletion following CSF1/CSF1R blockade. Mice bearing 1.0-cm orthotopic PyMT-derived tumors were treated with either αCSF1 or αCD11b neutralizing immunoglobulins (IgG) or with PLX3397. Treatment regimen is shown, and flow cytometric analysis of tumor-infiltrating D45⁺Ly6G⁻Ly6C⁻CD11b⁻F4/80⁺ macrophages and CD45⁺CD11b⁻Ly6G⁺IMCs is depicted as mean percentage of total cells ± SEM. B, selective depletion of TAMs following CSF1R kinase blockade. MMTV-PyMT mice (either 80 or 84 days old) were treated with PLX3397 for 4 or 8 days. Treatment regimen is shown, and flow cytometric analysis of tumor-infiltrating D45⁺Ly6G⁻Ly6C⁻CD11b⁻F4/80⁺ TAMs, D45⁺Ly6G⁺Ly6C⁻CD11b⁻CD11c⁺MHCII⁺DCs, and CD45⁺CD11b⁻Ly6G⁻IMCs in mammary tumors is depicted as mean percentage of total cells ± SEM. C, perivascular TAMs resisting PLX3397. Representative images of F4/80⁺ cell staining of mammary tumors from 30-day-old MMTV-PyMT mice treated with PLX3397 (vs control) for 8 days. Insets (a and b) show F4/80 staining in tumor stroma and tumor interior; (i), containing for F4/80 (red) and CD31 (green); scale bar, 500 μm. D, peripheral blood lymphocyte (PBL) migration in response to conditioned medium from MMTV-PyMT MECs treated with either vehicle or PTX (25 nM for 24 hours), evaluated by Boyden chamber assay. CD45⁺CD11b⁺ peripheral blood monocytes after migration to the lower chamber, in the presence or absence of PLX3397 (50 nM), as quantified by flow cytometry. Data are depicted as mean cell number assayed in triplicate. E, PTX-induced TAM recruitment inhibited by PLX3397. TAM density in mammary tumors removed from MMTV-PyMT mice following treatment with PTX ± PLX3397. Treatment regimen is shown with mouse age, and data are depicted as mean number of CD45⁺Ly6G⁻Ly6C⁻CD11b⁻F4/80⁺ TAMs as a percentage of total cells ± SEM (analyzed by flow cytometry, >5 mice/group). Representative IHC staining for F4/80 (red) and nuclear DNA (blue) from the same cohort of animals is shown. Scale bar, 500 μm; *, statistically significant differences (P < 0.05, Mann-Whitney) in A–E.
decreased by PLX3397/PTX therapy (Fig. 5C). This reprogramming of the immune microenvironment was accompanied by increased tumor infiltration of CD45+CD11b+CD19−Ly6G−Ly6C+CD11c+MHCII+ DCs (Fig. 3D), indicating that combined treatment of MMTV-PyMT mice with PLX3397/PTX fostered an antitumor immune response by T lymphocytes expressing high levels of cytotoxic effector molecules.

Given these findings, we assessed the capacity of TAMs (isolated from mammary tumors of MMTV-PyMT mice) to directly repress CD8+ T-cell activation in vitro. Using carboxyfluorescein succinimidyl ester (CFSE) dilution as a marker for T-cell proliferation, we found that CD45+CD11b+I4/80+Ly6G−Ly6C+ TAMs significantly repressed CD8+ T-cell activation and proliferation in a dose-dependent manner (Fig. 5E) that was reflective of the altered ratio of TAMs to CD8+ T cells in mammary tumors of untreated versus PLX3397/PTX-treated MMTV-PyMT mice (Fig. 5F).

One mechanism by which TAMs may suppress CD8+ T cells involves expression of inhibitory B7 family members that interact with “checkpoint” receptors expressed on infiltrating CD8 T cells. In particular, growing interest has been expressed in the PD1-PD1 ligand system, in which PD1/B7-H1 expression by TAMs represents a major source of the inhibitory PD1 ligand. Thus, we evaluated TAMs isolated from mammary tumors for expression of PD1/B7-H1 and PD12/B7-DC, as well as co-stimulatory molecules CD80 and CD86, and MHCII. TAMs expressed high levels of MHCII and B7-H1, but relatively lower levels of CD80 and CD86, indicating a possible role in inducing tolerance/anergy in tumor antigen-specific CD4+ and CD8+ T lymphocytes (Supplementary Fig. S5).

**Macrophage Depletion Enhances Chemotherapeutic Response in a CD8+ CTL-Dependent Manner**

To determine whether increased chemosensitivity of mammary tumors in PLX3397/PTX-treated mice was dependent on enhanced CD8+ T-cell response, we depleted CD8+ T cells from late-stage MMTV-PyMT mice treated with PTX or PLX3397 or both. Findings from this study revealed that the improved outcome with enhanced chemosensitivity resulting

---

**Figure 4.** Macrophage depletion improves response to chemotherapy. A and B, primary tumor growth reduced by treatment with macrophage-depleting agents in combination with chemotherapeutic. Orthotopic PyMT-derived tumors were grown to a median diameter of 1.0 cm, and mice were then treated with PTX, CBDCA, and/or αCSF1 or αCD11b neutralizing lgs (± PLX3397) for 21 or 28 days, with total tumor burden per animal assessed every 2 to 3 days. Treatment regimens are depicted for all cohorts, and data displayed as mean tumor burden ± SEM. **C**, statistically significant differences between vehicle- and PTX-treated mice. **D**, significant differences between mice treated with PTX alone and mice treated with PTX/PLX3397 or αCSF1 or αCD11b in combination. **E**, histologic stage analysis of MMTV-PyMT tumors. Tumors from 100-day-old MMTV-PyMT mice treated with PTX or PLX3397 or both were assessed for the presence of premalignant tissue and early- and late-stage carcinoma; data expressed as mean percentage of total gland area ± SEM. **F**, quantification of cleaved caspase-3-positive cells in mammary tumors of MMTV-PyMT mice treated with PTX or PLX3397 or both versus control (veh). Graph depicts mean positive cells per μm² of tumor tissue. Representative images show cleaved caspase-3-positive cells (brown staining) in tumors of MMTV-PyMT mice; scale bar, 500 μm. **E**, VEGF mRNA expression assessed by qRT-PCR of tumor tissue from MMTV-PyMT mice treated with vehicle or PTX or PLX3397 or both. Graph depicts mean fold change in gene expression compared with vehicle-treated control group. **F**, quantification of CD31-positive vessels in mammary tumors from MMTV-PyMT mice treated with PTX or PLX3397 or both, versus control (veh). Data represent the mean number of CD31-positive vessels per mm² of carcinoma tissue. Representative photomicrographs show CD31-positive vessels (brown staining); scale bar, 400 μm. *p*, statistically significant differences (P < 0.05, Mann-Whitney) in **C-F**.
Figure 5. PTX in combination with PLX3397 induces antitumor T-cell response. A and B, tumor infiltration by T lymphocytes enhanced by combined PTX and CSF1R or CSF1R blockade. Flow cytometric analyses of tumor infiltrating CD3+ CD8+ and CD3+ CD4+ T lymphocytes depicted as the mean number of positive cells, assessed as a percentage of total cells following treatment of MMTV-PyMT mice with PTX or PLX3397 or both (A), or treatment of mice having orthotopic PyMT-derived tumors with combined PTX/cCSF1 or PTX/PLX3397 (B), compared with controls. Mean values ± SEM are depicted. C, cytokine mRNA expression assessed in orthotopic PyMT-derived tumors from mice treated with PTX alone or in combination with PLX3397. Graph depicts mean fold change in mRNA expression compared with PTX treatment group (5 animals/group). SEM is depicted. D, tumor infiltration by DCs enhanced by combined PTX/PLX3397. Flow cytometric analysis of tumor-infiltrating CD45+Ly6G–Ly6C+CD11b+CD11c+ DCs depicted as mean percentage of positive cells as a percentage of total cells from MMTV-PyMT mice treated with PTX or PLX3397 or both, versus controls. E, CD8+ T-lymphocyte activation represened by TAMs. Purified T cells were loaded with CFSE and activated in vitro by plate bound CD3/28 and cocultured with the indicated ratio of CD45+Ly6G–Ly6C+CD11b+ F4/80+ TAMs isolated from late-stage mammary tumors of MMTV-PyMT mice. Data are depicted as the percentage of live CD8+ T lymphocytes exhibiting CFSE dilution after 72 hours. Data are representative of 2 independent experiments run in triplicate. Error bars represent SEM. F, analysis of the ratio of tumor-infiltrating CD45+Ly6G–Ly6C+CD11b+ F4/80+ TAMs to CD3+CD8+ T lymphocytes depicted as mean ratio (TAM/CD8 T cells) ± SEM from MMTV-PyMT mice treated with vehicle or with PTX and/or PLX3397. Statistical significance was calculated using a t-test with Mann-Whitney (A–F). **, statistically significant differences (P < 0.05, Mann-Whitney) in A–F. *, statistically significant differences (P < 0.05, Mann-Whitney) between PLX3397-treated groups in F.

from combined PLX3397/PTX therapy was indeed a CD8+ T-cell-dependent response (Fig. 6A and B; Supplementary Fig. S8B). We found that CD8 depletion also resulted in increased tumor grade and decreased presence of cleaved caspase-3–positive cells in mice that had received combined PLX3397/PTX therapy (Fig. 6C and D). Taken together, these data indicate that the enhanced cytotoxic response elicited by CSF1R-signaling blockade was CD8+ T-cell-dependent.

Combined Macrophage Depletion and Chemotherapy Blocks Metastasis in a CD8-Dependent Manner

Long-term survival of breast cancer patients is often limited by disseminated metastases following surgical resection of primary tumors. Analysis of leukocyte profiles in human breast cancer tissues demonstrated that OS, and thus presumably metastatic spread, were regulated by the spectrum of tumor-infiltrating T lymphocytes and macrophages present. In MMTV-PyMT mice, although neither CSF1R-signaling blockade nor PTX therapy alone inhibited development of pulmonary metastases, mice receiving combined PLX3397/PTX exhibited >85% reduction in pulmonary metastases that was in part CD8+ T-cell–dependent (Fig. 6E).

Macrophages and CD8 Infiltration Predicts Survival and Chemotherapeutic Response

Overall, our data indicated that in the absence of TAMs, antitumor CD8+ CTLs bolster response to chemotherapy and thereby influence outcome; thus, we predicted that TAM and CD8 T-cell ratios would correlate with pathologic responses in patients with breast cancer. Accordingly, we analyzed CD68 and CD8a mRNA expression in a cohort of 311 patients constructed from 2 independent datasets (26, 27). All patients provided fine-needle aspirates (FNA) prior to neoadjuvant chemotherapy, and pathologic response was assessed at the time of definitive surgery. CD8 mRNA expression in FNA samples correlated with pathologic complete response (pCR; R = 0.216; P < 0.001); however, CD68 did not. With median expression as a threshold, examination of both CD8 and CD68 mRNA revealed 3 groups—CD68 > CD8, CD68 < CD8, and CD68 = CD8 (denoted CD68ab/CD8bc, CD68ab/CD8ab, and CD68ab/CD8bc).
CD8^\text{low}/CD68^\text{high} group correlating with a significantly lower rate of pCR (7%) and the CD68^\text{low}/CD8^\text{low} group exhibiting the highest rate of pCR at 27% (Fig. 7A). Thus, the ratio of CD68/CD8\text{low} expression represents a predictive response biomarker for neoadjuvant chemotherapy.

We next evaluated CD68 and CD8\text{low} mRNA expression in breast cancers representing ~4000 patients assembled from 22 retrospective gene expression datasets (Supplementary Table S8). Median expression for both CD8\text{low} and CD68 was used to determine high and low groups. All patients were categorized as either CD68^\text{high}/CD8\text{low} or CD68^\text{low}/CD8^\text{low}. Kaplan-Meier estimates of survival demonstrated significantly reduced OS in the CD68^\text{low}/CD8\text{low} group (Fig. 7B). Not surprisingly, these gene expression results were validated using Kaplan-Meier analysis of OS on IHC data from Cohort I and II stratified for CD68^\text{high}/CD8\text{low} or CD68^\text{low}/CD8^\text{low} (Supplementary Fig. S9A and B).

Because breast cancer represents a spectrum of distinct molecular subtypes (luminal A, luminal B, HER2-positive, basal type/triple negative), possessing distinct histopathologic and molecular features and correlating with differential responses to therapy and outcome (28–30), we evaluated CD68/CD8\text{low} expression within breast cancer subtypes. CD68^\text{low}/CD8\text{low} expression correlated with reduced OS for breast cancer patients whose tumors were classified as either basal or HER2-positive (Fig. 7C; Supplementary Fig. S10).
DISCUSSION

The immune microenvironment in which a tumor evolves influences multiple parameters of the tumorigenic process. In this article we demonstrate that the immune microenvironment in breast cancer is a predictor of RFS and OS. Moreover, we provide evidence that response to chemotherapy is in part regulated by the immune microenvironment and that cytotoxic therapies induce neoplastic cells to produce monocytic/macrophage recruitement factors, including CSF1 and IL-34, which in turn enhance CSF1R-dependent macrophage infiltration into mammary adenocarcinomas. This is significant in light of our finding that blockade of the CSF1-signaling pathway mediating TAM recruitment, in combination with chemotherapy, decreases primary tumor progression, reduces metastasis, and improves survival—a CD68+ T-cell-dependent outcome resulting from a reprogrammed immune microenvironment that fosters antitumor immunity. These data provide a compelling rationale for combinatorial therapies targeting TAM recruitment, notably CSF1R-mediated signaling pathways, in combination with cytotoxic therapy for breast cancer.

The Immune Microenvironment in Breast Cancer Predicts Outcome

In a previous study, we reported that T-helper 2 (Th2)-CD4+ T-effector cells regulate TAM biactivity and thereby promote late-stage mammary carcinogenesis and development of pulmonary metastasis (11). We now extend these findings and demonstrate that the complexity of CD8+ T lymphocytes, CD4+ T lymphocytes (presumably CD4+ T regulatory cells or both), and CD68+ TAMs is a predictive biomarker for OS and RFS in node-positive breast cancer (Fig. 1). Retrospective clinical studies have previously revealed that the ratio of CD4+ to CD8+ T lymphocytes, or CD4+ to CD8+ T cells, infiltrating breast cancer correlates with increased tumor grade, lymph node metastasis, and reduced OS (31). Unsupervised expression profiling of breast cancer-associated stroma revealed a gene signature predictive of good prognostic outcome (>98% 5-year survival) that was functionally enriched for genes suggestive of CTL and natural killer cell activity (32). Moreover, elucidation of a CSF1-response gene expression signature in breast cancer demonstrated that CSF1 signaling correlates with response to therapy and OS (7–9). In this article, we revealed that not only does increased macrophage density correlate with poor outcome (Fig. 1), as reported by others, as well (5, 31, 33), but also the ratio of macrophages/CD68+ to CD8+ T lymphocytes/CD68+ in breast cancer is inversely correlated, an important finding when considering that TAMs can also suppress antitumor immunity. These findings indicate that our immune-based signature may be a useful predictor of recurrence and poor OS for multiple breast cancer subtypes, and, as such, may improve existing gene expression-based prognostic profiling to evaluate risk.

Breast Cancer CSF1 and CSF1R Expression

Our findings demonstrate that macrophage CSF1R signaling is necessary for their recruitment following induction of CSF1 mRNA and interaction with ligand in carcinoma cells treated with chemotherapy (Fig. 3). Recent studies by Patsalou and colleagues (34) demonstrated that in some human breast carcinoma cell lines, specifically MDA-MB231, steady-state CSF1 mRNA is expressed at high levels and autocrine CSF1-CSF1R signaling enhances invasion (44). Notably, MDA-MB231 cells in our studies did not respond to CTX with increased CSF1 mRNA expression (Fig. 3), likely because these cells already express 10- to 50-fold higher levels of CSF1 mRNA than do other breast cancer cell lines evaluated (data not shown). Carcinoma cells isolated from MMVTPyMT mice do not express significant levels of CSF1R mRNA (15, 22), indicating that CSF1R blockade in MMVTPyMT mice influences myeloid biology, as opposed to MECs.

Figure 7. Ratio of CD68 to CD8 predicts patient survival and response to neoadjuvant chemotherapy. A, frequency of pCR in a cohort of 311 patients constructed from 2 independent datasets. All patients received FNA s prior to neoadjuvant chemotherapy and pathologic response was assessed at definitive surgery. With median expression as a threshold, examination of CD68 and CD68 mRNA in FNA samples revealed 3 separate groups: CD68 > CD8, CD68 = CD8, and CD68 < CD8 (denoted CD68+h/CD68h, CD68=m/CD68m, and CD68+l/CD68l, respectively). Analysis of the ratio of CD68+ to CD8+ T lymphocytes, or CD6+ to CD8+ T cells, infiltrating breast cancer correlates with increased tumor grade, lymph node metastasis, and reduced OS (31). Unsupervised expression profiling of breast cancer-associated stroma revealed a gene signature predictive of good prognostic outcome (>98% 5-year survival) that was functionally enriched for genes suggestive of CTL and natural killer cell activity (32). Moreover, elucidation of a CSF1-response gene expression signature in breast cancer demonstrated that CSF1 signaling correlates with response to therapy and OS (7–9). In this article, we revealed that not only does increased macrophage density correlate with poor outcome (Fig. 1), as reported by others, as well (5, 31, 33), but also the ratio of macrophages/CD68+ to CD8+ T lymphocytes/CD68+ in breast cancer is inversely correlated, an important finding when considering that TAMs can also suppress antitumor immunity. These findings indicate that our immune-based signature may be a useful predictor of recurrence and poor OS for multiple breast cancer subtypes, and, as such, may improve existing gene expression-based prognostic profiling to evaluate risk.

Breast Cancer CSF1 and CSF1R Expression

Our findings demonstrate that macrophage CSF1R signaling is necessary for their recruitment following induction of CSF1 mRNA and interaction with ligand in carcinoma cells treated with chemotherapy (Fig. 3). Recent studies by Patsalou and colleagues (34) demonstrated that in some human breast carcinoma cell lines, specifically MDA-MB231, steady-state CSF1 mRNA is expressed at high levels and autocrine CSF1-CSF1R signaling enhances invasion (44). Notably, MDA-MB231 cells in our studies did not respond to CTX with increased CSF1 mRNA expression (Fig. 3), likely because these cells already express 10- to 50-fold higher levels of CSF1 mRNA than do other breast cancer cell lines evaluated (data not shown). Carcinoma cells isolated from MMVTPyMT mice do not express significant levels of CSF1R mRNA (15, 22), indicating that CSF1R blockade in MMVTPyMT mice influences myeloid biology, as opposed to MECs.
Immunosuppressive Macrophages and Chemosensitivity

Development and progression of pulmonary metastases in mammary carcinoma is impaired in mice containing a recessive null mutation in the CSF1 gene (15, 35). Similarly, blockade of CSF1R signaling impairs aspects of mammary carcinogenesis (36) and metastases (37). We used αCSF1 mAb and PLX3397, a novel small-molecular-weight tyrosine kinase inhibitor, to efficiently deplete CD11b+Ly6G−Ly6C<sup>high</sup>F4/80<sup>+</sup> TAMs (70%) without altering the presence of CD11b<sup>+</sup>Ly6C<sup>low</sup>F4/80<sup>+</sup> iMCs or perivascular F4/80<sup>+</sup> macrophages in mammary tumor stroma (Fig. 3).

Malignant mammary epithelial cells from MMTV-PyMT mice express high levels of CSF1, which directly regulates TAM recruitment (and EGF expression) and induction of macrophage HIF1α (11, 38, 39). We previously reported that IFN-γ<sup>+</sup> CD8<sup>+</sup> CTL activity is impaired by myeloid-derived ARG1 and nitric oxide synthase that is HIF1α-dependent (38). Thus, on the basis of inverse correlation between TAMs and CD8<sup>+</sup> T cells in human breast cancer, and the fact that TAMs infiltrating mammary carcinomas directly suppress CTL activity in a HIF1α-dependent manner (38), we postulated that TAM depletion would foster antitumor immunity by relieving TAM-mediated CTL suppression and thereby enhance response to cytotoxic therapy. Accordingly, combined treatment of MMTV-PyMT mice with PTX, and either αCSF1 mAb or PLX3397, slowed primary tumor development, reduced development of high-grade carcinomas (Fig. 4), and decreased pulmonary metastasis by 85% (Fig. 6), features of mammary carcinogenesis accompanied by decreased vascular density (Fig. 4), and increased CD4<sup>+</sup> and CD8<sup>+</sup> T-cell infiltration in primary tumors (Fig. 5). Increased presence of CD8<sup>+</sup> T cells was significant in this regard, as when specifically depleted, the added benefit of combined PLX3397/PTX therapy was lost (Fig. 6).

Immunosuppressive myeloid cells encompass a diverse population of CD11b<sup>+</sup>Gr1<sup>+</sup>Ly6G<sup>+</sup> cells, including myeloid-derived suppressor cells, inflammatory monocytes, neutrophils, and iMCs. Human equivalents have been identified as LIN<sup>−</sup>/low human leukocyte antigen (HLA)-DR−CD33<sup>−</sup>CD11b<sup>+</sup> and CD14<sup>+</sup>HLA-DR−/low iMCs (40). CSF1R blockade by PLX3397 depleted CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>high</sup>F4/80<sup>+</sup> TAMs, but not CD11b<sup>+</sup>Ly6G<sup>+</sup> cells (Fig. 3C), which are 12-fold less abundant in MMTV-PyMT carcinomas. In contrast, immunosuppressive CD11b<sup>+</sup>Ly6G<sup>+</sup> cells are more abundant in other mammary tumor models, such as 4T1 (41). This may be an important distinction between tumor types considering the fact that monocyte mobilization from bone marrow is impaired by genetic loss of genes synthase that is HIF1α-dependent (38). Thus, on the basis of inverse correlation between TAMs and CD8<sup>+</sup> T cells in human breast cancer, and the fact that TAMs infiltrating mammary carcinomas directly suppress CTL activity in a HIF1α-dependent manner (38), we postulated that TAM depletion would foster antitumor immunity by relieving TAM-mediated CTL suppression and thereby enhance response to cytotoxic therapy. Accordingly, combined treatment of MMTV-PyMT mice with PTX, and either αCSF1 mAb or PLX3397, slowed primary tumor development, reduced development of high-grade carcinomas (Fig. 4), and decreased pulmonary metastasis by 85% (Fig. 6), features of mammary carcinogenesis accompanied by decreased vascular density (Fig. 4), and increased CD4<sup>+</sup> and CD8<sup>+</sup> T-cell infiltration in primary tumors (Fig. 5). Increased presence of CD8<sup>+</sup> T cells was significant in this regard, as when specifically depleted, the added benefit of combined PLX3397/PTX therapy was lost (Fig. 6).

Immunosuppressive myeloid cells encompass a diverse population of CD11b<sup>+</sup>Gr1<sup>+</sup>Ly6G<sup>+</sup> cells, including myeloid-derived suppressor cells, inflammatory monocytes, neutrophils, and iMCs. Human equivalents have been identified as LIN<sup>−</sup>/low human leukocyte antigen (HLA)-DR−CD33<sup>−</sup>CD11b<sup>+</sup> and CD14<sup>+</sup>HLA-DR−/low iMCs (40). CSF1R blockade by PLX3397 depleted CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>high</sup>F4/80<sup>+</sup> TAMs, but not CD11b<sup>+</sup>Ly6G<sup>+</sup> cells (Fig. 3C), which are 12-fold less abundant in MMTV-PyMT carcinomas. In contrast, immunosuppressive CD11b<sup>+</sup>Ly6G<sup>+</sup> cells are more abundant in other mammary tumor models, such as 4T1 (41). This may be an important distinction between tumor types considering the fact that monocyte mobilization from bone marrow is impaired by genetic loss of genes synthase that is HIF1α-dependent (38). Thus, on the basis of inverse correlation between TAMs and CD8<sup>+</sup> T cells in human breast cancer, and the fact that TAMs infiltrating mammary carcinomas directly suppress CTL activity in a HIF1α-dependent manner (38), we postulated that TAM depletion would foster antitumor immunity by relieving TAM-mediated CTL suppression and thereby enhance response to cytotoxic therapy. Accordingly, combined treatment of MMTV-PyMT mice with PTX, and either αCSF1 mAb or PLX3397, slowed primary tumor development, reduced development of high-grade carcinomas (Fig. 4), and decreased pulmonary metastasis by 85% (Fig. 6), features of mammary carcinogenesis accompanied by decreased vascular density (Fig. 4), and increased CD4<sup>+</sup> and CD8<sup>+</sup> T-cell infiltration in primary tumors (Fig. 5). Increased presence of CD8<sup>+</sup> T cells was significant in this regard, as when specifically depleted, the added benefit of combined PLX3397/PTX therapy was lost (Fig. 6).

Tissue Specificity and Clinical Implications

Stromal infiltration of TAMs is a poor prognostic indicator for some solid tumor types (43); however, infiltration of TAMs inside tumor nests, particularly when CD8<sup>+</sup> CTLs are also present, can correlate with improved survival outcome (44). These differences might be explained in part by the fact that TAMs produce either protumor or antitumor bioactivities depending on the types of cytokines to which they are exposed (43). TAMs regulated by Th1 cytokines including IFN-γ, TNF-α, and granulocyte monocyte colony stimulating factor enhance TAM cytotoxic activity, production of proinflammatory cytokines, and antigen presentation (45). In contrast, tissue macrophages exposed to Th<sub>2</sub> cytokines, immune complexes, or immunosuppressive cytokines instead block CTL activity and promote angiogenesis and tissue remodeling (43, 45). In non–small cell lung cancer, TAMs that localize to tumor nests and correlate with favorable clinical outcomes exhibit an M1/Th1 cytokine profile and express high levels of HLA-DR (46, 47). In contrast, CD163 and CD204 expressing TAMs (M2/Th<sub>2</sub> markers) correlate with poor clinical outcomes in melanoma, non–small cell lung cancer, and pancreatic cancer (48, 49). We found that tumor tissue from PLX3397/PTX-treated mice had increased IL12p35 and IENox1 mRNA expression, indicative of bolstered antitumor immunity, indicating that PLX3397/PTX therapy fostered a general reprogramming of the immune microenvironment, in addition to blocking TAM infiltration that together favored CD8<sup>+</sup> T-cell-mediated tumor suppression. Data presented herein do not reveal whether the improved outcome for tumor-bearing mice or the antitumor immune microenvironment fostered under these conditions resulted directly from reduced presence of alternatively activated TAMs, decreased vessel density, or a combination of the two.

Given the fact that PLX3397 as monotherapy efficiently reduced TAM presence but had no effect on vessel density, primary carcinoma (Fig. 4), or pulmonary metastasis development (Fig. 6), it seems reasonable to speculate that TAM depletion resulted in loss of an important epithelial cell survival pathway (possibly mediated by EGF) that resists chemotherapy-induced cell death; certainly, however, effects on vascular pathways may also play a role, as has been recently reported by Rolny and colleagues (50). It will be interesting to determine whether directly reprogramming TAMs—for example, by neutralization of IL-4—to favor the presence of classically activated (M1) TAMs, as we have previously reported (11), also similarly enhances antitumor immune programs and chemosensitivity and, if so, whether those responses are also CD8<sup>+</sup> T-cell–dependent.

Microtubule inhibitors constitute one of the most effective classes of cytotoxic agents available for treating both early- and late-stage breast cancer, and are considered the standard of care for treatment of metastatic disease. Several agents that affect microtubule dynamics are active antitumor agents and induce polymerization or cause nonfunctional tubulin aggregates. These compounds block cell division by interfering with function of the mitotic spindle and consequently result in cell-cycle arrest and cell death. PTX is among the most widely used agents in this class. Despite the clinical activity of taxanes, median time to progression in patients treated with PTX is only 6 to 9 months in the first- and second-line setting, and 3 to 4 months in patients with previous exposure to taxanes (51). Although addition of the antiangiogenic agent bevacizumab to PTX improved response and time to progression, it was without impact on OS (52). Glucocorticoid premedication is required for PTX to prevent increased bone marrow and peripheral nerve toxicity as well as allergic reactions and anaphylaxis due to the Cremaphor solvent base. For other cytotoxic agents, glucocorticoids are also commonly used to prevent
totoxicities such as nausea, vomiting, and fluid retention. Although these agents are standard additions to many chemotherapies, they suppress production of proinflammatory cytokines and chemokines, severely impair differentiation of antigen presentation by DCs, suppress development of Th1 cells, and bias immune responses toward Th2 cell types (53). Our neoadjuvant studies in MMTV-PyMT and orthotopic tumor-bearing mice were performed without dexamethasone, an H2 antagonist, or diphenhydramine. Thus, it is possible that the CD8+ T-cell-dependent antitumor program fostered by combined PLX3397/PTX would have been dampened in the presence of dexamethasone. An understanding of the mechanisms that lead to inadequate or poor response to taxanes is urgently needed, as are prognostic biomarkers that predict which patients will respond favorably. That said, it seems reasonable that administration of cytotoxic agents not requiring steroids, in combination with novel strategies such as TAM ablation (or TAM reprogramming), which together bolster status, may benefit most from such therapies.

**METHODS**

**Patients and Tumor Samples**

Tissue microarray studies were conducted on 2 separate patient cohorts. The screening cohort, Cohort I, described elsewhere in detail (54), was constructed from 179 cases of invasive breast cancer diagnosed at the Department of Pathology, Malmo University Hospital, Malmo, Sweden, between 2001 and 2002. The median age at diagnosis was 65 years of age, and the median follow-up time for OS was 54 months. Patients had not received neoadjuvant therapy and were treated with either modified radical mastectomy or wide local excision. The clinical outcome of pharmacologically (or immunologically) targeting TAMs directly or the pathways that regulate their recruitment must be considered carefully because all cancer types may not respond in a similar fashion. This study provides a compelling rationale for clinical evaluation of combination therapies inhibiting TAM recruitment, in combination with standard-of-care chemotherapy for treatment of breast cancer, and underscores the importance of identifying a population of patients who, by virtue of their immune profile and CSF1R status, may benefit most from such therapies.

**Neoadjuvant Cohort**

The neoadjuvant cohort consisted of 2 gene expression cohorts representing 311 patients treated with neoadjuvant chemotherapy (26, 27), with complete pathologic response in 60 (19%) patients. The majority of patients received PTX and fluorouracil-doxorubicin-cyclophosphamide. Both datasets were examined on the same array platform (Affymetrix U133A), using a standard operating procedure and normalization method (dCHIP) as previously reported (57, 58). Data were downloaded from the Gene Expression Omnibus (59) and an institutional website (60). Normalized expression values for both CD8 and CD68 were established as previously described (54).

**Preclinical Mouse Models and Animal Husbandry**

Mice harboring the PyMT transgene under the control of the MMTV promoter in the FVB/n strain were obtained from Dr. Zena Werb [University of California, San Francisco (UCSF), San Francisco, California] and have been previously described (14). Two murine models of mammary tumor development were used to analyze response to chemotherapy (Supplementary Fig. S3). The first model used MMTV-PyMT mice (Supplementary Fig. S3A). The 80-day-old MMTV-PyMT female littermates were randomized by initial tumor volume and fed either PLX3397 (20, 61, 62) formulated in mouse chow or control chow (provided by Plexonik Inc). PLX3397 was formulated in mouse chow so that the average dose per animal per day was 40 mg/kg. When PLX3397-treated MMTV-PyMT mice reached 85 days of age, they were then administered PTX (Hospira) every 5 days by iv injection into the retroorbital plexus. PTX was given at 10 mg/kg of the animal per injection, diluted in PBS. Tumor burden was evaluated by caliper measurement every 5 days following the start of PLX3397 treatment. Prior to tissue collection, mice were cardiopulmonary-perfused with PBS to clear peripheral blood. Mammary tumor tissue from PBS-perfused MMTV-PyMT mice was analyzed by flow cytometry and qRT-PCR 2 days after the second dose of PTX, when metastatic burden and tumor grade were determined. Primary tumor burden was determined by caliper measurements on live sedated mice. Metastatic burden was assessed by serial sectioning of formalin-fixed paraffin-embedded lung tissue whereby the entire lung was sectioned and the number of metastatic foci (>5 cells) was determined on 6 sections taken every 100 μm following H&E staining. Lungs from >10 mice/group were analyzed.

**Automated Image Acquisition, Management, and Analysis**

Fully automated image acquisition was used for the results presented in this article. The Aperio ScanScope XT Slide Scanner (Aperio Technologies) was used to capture whole-slide digital images with a 20X objective. Slides were dehydrated to visualize individual cores, using Spectrum software (Aperio). A tumor-specific nuclear algorithm (IHC-MARK) developed in house was modified to quantify CD4, CD8, and CD68 expression. IHC-MARK was initially designed to identify tumor cells on the basis of nuclear morphologic features (56); however, this was modified for evaluating leukocyte infiltration based on specific nuclear morphologic features.

**Image and Statistical Analysis**

A decision tree-supervised algorithm was used to group patients based on immune cell IHC density. For decision tree analysis, all patients were randomly divided into 10 subsets. A decision tree model was selected using a 10-fold cross-validation approach (16). Ten consecutive decision tree models were independently constructed with the immune cell infiltration density continuous output from 9 subsets. Survival outcome predictive power of each decision tree model was tested on the remaining set of patients, and the model with the higher accuracy was selected as optimal for the dataset. Kaplan-Meier analysis and the log-rank test were used to illustrate differences between OS and RFS according to individual CD68, CD4, and CD8 expression. A Cox regression proportional hazards model was used to estimate the relationship to OS of the CD68/CD4/CD8 immune profile; lymph node status; tumor grade; and HER2, PR, and ER status in the patient cohort. A P value of <0.05 was considered statistically significant, and calculations were assessed using Statistical Package for the Social Sciences (SPSS, Inc.).
To assess tumor grade, the stage characterization technique classified tumor tissue into 3 levels of histologic progression by quantifying the area of transformed glands occupied by each stage (15, 38). Progression follows from a “precancerous stage” characterized by premalignant hyperplasia and adenoma/mouse intestinal epithelium but with the retention of some normal ductal and acinar mammary gland morphology, to a more epithelial cell–dense “early carcinoma” with some stromal invasion, and finally to an invasive, high–mitotic index “late-stage carcinoma.” The IHC analysis was conducted on tissue sections following the end of studies on 100-day-old MMTV-PyMT mice (detailed in Supplementary Fig. S4A). Vehicle-treated mice received PBS-only injections. We also used a syngeneic orthotopic implantable tumor model (referred to as PyMT-implantable in all figures and detailed in Supplementary Fig. S4B). For this model, single-cell suspensions of tumor cell pools isolated from mammary tumors of 3 or 4 100-day-old MMTV-PyMT mice were generated following collagenase A digestion (see discussion of flow cytometry analysis earlier). A total of 1.0 million tumor cells from pools were diluted in medium and basement membrane extract (Matrigel, BD Pharmingen) and injected orthotopically into unclued mammary fat pads (4th gland) of 10-week-old virgin FVB/n female mice. Following implantation, tumors were allowed to grow to a mean diameter of 1.0 cm before enrollment into studies. Mice were randomized into treatment groups based on tumor size and treated with PLX3397 and PTX, as described above. For some studies, CBDCa (Hospira) was used and administered at 10 mg/kg of mouse per injection, in a similar manner to administration of PTX (see above). For mice with implantable tumors, tumor burden was evaluated by caliper measurement every 2 to 3 days following the start of PLX3397 treatment, and mammary tissue was analyzed by flow cytometry, IHC, and qRT-PCR at the end of the study (Supplementary Fig. S3B). Immune-depleted mice were injected i.p. every 5 days with either 1.0 mg anti-CD8 immunoglobulin G (YTS169.4) or isotype control rat immunoglobulin on day 1 followed by 500 μg every 5 days. All mice were maintained within the UCSF Laboratory for Animal Care barrier facility, and the UCSF Institutional Animal Care and Use Committee approved all experiments involving animals.

Additional information on methods and cohorts is available in the Supplementary Data.

Disclosure of Potential Conflicts of Interest

E. Rexhepaj, D.J. Brennan, and W.M. Gallagher are inventors of a pending patent application in relation to the development of novel automated image analysis approaches in histopathology, and D.G. DeNardo, D.J. Brennan and L.M. Coussens are inventors of a pending patent application in relation to immune-based signatures for predicting breast cancer risk. B.L. West is an employee of Plexxikon Inc. but had no involvement in data collection, analysis, or interpretation.

Acknowledgments

The authors thank the UCSF Helen Diller Family Comprehensive Cancer Center Laboratory for Cell Analysis and Mouse Pathology shared resource core facilities; members of the Coussens lab for critical discussion; and Plexxikon Inc. for providing PLX3397.

Grant Support

This work was supported by the American Cancer Society and National Cancer Institute Postdoctoral Training Grants (D.G. DeNardo); Department of Defense Breast Cancer Research Program and a Dr. Susan Love Research Foundation Instructional Grant (R. Ruffell); Breast Cancer Research Foundation (H.S. Rugo); and The University College Dublin Conway Institute, which is funded by the Programme for Research in Third Level Institutions, as administered by the Higher Education Authority of Ireland. Funding is acknowledged from Enterprise Ireland (D.J. Brennan, E. Rexhepaj, and W.M. Gallagher); Science Foundation Ireland Strategic Research Cluster award to Molecular Therapeutics for Cancer Ireland (W.M. Gallagher and S.F. Madden); and NIH/National Cancer Institute Grants R01CA130980, R01CA132566, R01CA140943, and P50CA58207, and the Department of Defense Grants W81XWH-06-1-0416 and PR080717 (L.M. Coussens).

Received November 30, 2010; revised February 7, 2011; accepted February 8, 2011; published OnlineFirst April 3, 2011.

REFERENCES

Macrophages Regulate Response to Chemotherapy


